








Mona N. Bahouth 
 
 
A dissertation submitted to Johns Hopkins University School of Nursing in conformity 








© 2019 Mona Bahouth 








Stroke is a leading cause of adult disability with only a few therapies (e.g. intravenous tissue 
plasminogen activator) proven to impact functional outcomes. An estimated 36-56% of patients 
presenting to the hospital with acute ischemic may be dehydrated, volume depleted, or both, as 
estimated by serological and clinical markers. Hydration status at the time of stroke appears to 
be an important determinant of worsened stroke outcomes. No mechanism has been firmly 
identified for this relationship, nor is it clear whether these alterations might particularly impact 
efficacy of acute stroke treatments, leading to variability in its benefit. This dissertation 
comprises parallel studies intended to explore the relationship between hydration status at the 
time of stroke and the degree of benefit from hyperacute stroke therapies. This work will inform 
future intervention studies focused on the potential benefit of early rehydration after stroke. The 
development of an inexpensive and globally available treatment, like targeted rehydration 
therapy, has the potential to reduce disability and improve quality of life for patients with stroke. 
 
In the first two aims, we sought to understand the relationship between baseline hydration status 
and stroke outcomes after two approved hyperacute stroke treatments: tissue plasminogen 
activator (medication) and mechanical thrombectomy (surgery). Aim three focuses on the 
feasibility and acceptability of using a non-invasive cardiac output monitor to evaluate hydration 
status using a marker of potential fluid responsiveness. To achieve these aims, we evaluated 
outcomes from three separate cohorts of stroke patients: (1) a retrospective group of patients 
treated with tissue plasminogen activator; (2) a retrospective group of patients treated with 
mechanical thrombectomy; and (3) a prospective group of patients evaluated with a noninvasive 
cardiac output monitor. Together, these data broaden the understanding of the relationship 
between hydration status at the time of stroke and stroke recovery. These data will inform the 
development of a potential intervention to modify that relationship in future studies. 
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This dissertation contains six chapters. The first chapter provides background, conceptual 
framework for this work, summary of study aims. Chapter 2 (Manuscript 1) is a review of the 
current state of the science in the area of dehydration and ischemic stroke outcome. It is published 
in the Journal of Neurology. Chapters 3-5 are (Manuscripts 2, 3, 4) are data based manuscripts 
that provide results for aims 1,2 and 3. They are pending submission. Chapter 6 summarizes 
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Surrogate blood markers suggesting an alteration in hydration status; 
BUN/Creatinine ratio 15 may suggest at least mild dehydration (a 
volume contracted state). These are commonly collected at the time 
of hospitalization for most patients. 
Mechanical 
thrombectomy 
Surgical endovascular procedure to withdraw an obstructive blood 
clot from a large vessel that is causing a stroke in the brain. 
Modified Rankin Scale 
(mRS) 
Scale commonly used to rate functional outcome after stroke 
National Institutes of 
Health Stroke Scale 
Score (NIHSSS) 
Quantification of the neurological examination to communicate stroke 
severity 
Neglect syndrome Neurologic deficit common in large artery occlusion that places the 
patient at high risk for falls and poor functional recovery due to 
interference with the patient’s ability to participate in rehab therapy 
Noninvasive cardiac 
monitor (NICOM) 
An external device used to measure intravascular volume status. This 
technology will be tested for feasibility of use in the stroke population. 
Stroke Clinical syndrome consistent with sudden death of brain cells due to 
lack of oxygen caused by disrupted blood flow to that region of the 
brain; diagnosis suspected by vascular specialist at the time of 
hospital presentation 
Treatment in Cerebral 
Infarction (TICI) 
Grading system used to determine response to stroke treatment 




The only FDA approved medical therapy for acute ischemic stroke. 
This intravenous drug must be administered within 4.5 hours from the 




Descriptor used to describe the hydration variable of interest. This is 








Chapter 1. Introduction 
Stroke is common and a leading worldwide cause of adult disability, with few therapies proven 
to impact functional outcome.1 To date intravenous tissue plasminogen activator (tPA) is the 
only FDA approved medication for the treatment of acute ischemic stroke and mechanical 
embolectomy is the only approved surgical intervention, though benefit of these treatments has 
been variable.2 Increasing evidence suggests that dehydration, or more accurately, a volume 
contracted state (VCS) is common at the time of acute ischemic stroke and contributes to a 
worsened functional outcome.3-6 An estimated 36-56% of patients presenting to the hospital with 
acute ischemic may be dehydrated, volume depleted, or both, as estimated by serological and 
clinical markers. Furthermore, volume contraction may be a risk factor for early clinical 
worsening. A VCS likely impacts a stroke patient in a variety of ways including alterations in 
medication pharmacodynamics, disrupted cerebral perfusion, and altered distribution of 
inflammatory markers. No mechanism has been firmly identified for this relationship, nor is it 
clear whether these alterations might particularly impact efficacy of acute stroke treatments, 
leading to variability in its benefit.  
 
Diagnosing a VCS remains highly subjective. Noninvasive cardiac output monitors (NICOM) 
are used in the management of patients with acute hydration issues (e.g. sepsis) to provide 
objective, real-time data about intravascular volume status. In early stroke care, surrogate 
serum chemistries are most often used to evaluate for the presence of a VCS. In our pilot 
studies, acute ischemic stroke patients in VCS, defined by serologic patterns, had a worse 
short-term clinical outcome measured at the time of hospital discharge than euvolemic patients.7 
In clinical practice, however, hydration practices in after acute stroke are often conservative due 
to concerns of precipitating heart failure or cerebral edema. Using a serum levels to measure 
hydration more precisely is invasive, painful, with time-delayed results. Guidance for more 
precise rehydration interventions are limited partly by uncertainty surrounding measures for 
clinical volume status and lack of a mechanistic rationale for the relationship between VCS and 
worsened stroke outcome. This knowledge gap offers an important opportunity for further study. 
 
The overarching goal of this research was to examine the potential for early and expedited 
rehydration to improve functional outcome after stroke. Specifically, we evaluated if hydration 




2) interferes with revascularization during mechanical embolectomy; 3) can be measured 
objectively and noninvasively, using noninvasive cardiac output monitoring (NICOM).  
 
The proposed study evaluates an important relationship between hydration status and 
outcomes and will inform the development of a future technology-supported clinical trial of 
intervention strategies aimed at improving stroke outcomes. To accomplish these objectives, we 
had the following aims:  
 
Specific Aim 1. To determine whether the benefit of tPA differs in volume contracted versus 
euvolemic acute ischemic stroke patients.  
A retrospective analysis of a prospective cohort of consecutive ischemic stroke patients 
presenting to the Johns Hopkins comprehensive stroke centers within 4.5 hours over 5 years.  
Hypothesis 1.1: VCS patients treated with tPA will have less benefit (less likely to achieve a 
modified Rankin Scale (mRS) 0-2) than euvolemic patients treated with tPA, each compared to 
non-tPA receiving counterparts after controlling for demographic and disease specific 
covariates.  
Hypothesis 1.2: VCS patients treated with tPA will have more clinical complications including 
fluctuation in neurological examination defined as increase in NIHSS >3 and intracerebral 
hemorrhage than will euvolemic tPA-treated patients.  
 
Specific Aim 2. To compare rates of successful revascularization for acute ischemic stroke in 
volume contracted and euvolemic patients.  
A retrospective analysis of a prospective cohort of consecutive ischemic stroke patients 
presenting to the Johns Hopkins comprehensive stroke centers within 6 hours over 5 years.  
Hypothesis 2.1: Acute ischemic stroke patients in a VCS at the time of mechanical embolectomy 
will have lower rates of successful revascularization (> TICI2a) compared to euvolemic patients 
undergoing embolectomy. 
Exploratory hypothesis: Among ischemic stroke patients undergoing mechanical embolectomy, 
those patients in a VCS at the time of the procedure will more early neurological worsening and 
intracerebral hemorrhage than similar patients who are euvolemic at the time of the procedure. 
 
Specific Aim 3. To test the feasibility of noninvasive cardiac output monitoring to measure the 
frequency of VCS among hospitalized patients with acute ischemic stroke.  




Hypothesis 3.1: Measuring hydration status with NICOM will be feasible and acceptable to 
hospitalized stroke patients 
Hypothesis 3.2: Fluid responsiveness will be detected by NICOM at a similar frequency as lab-
measured VCS (BUN/creatinine ratio > 15).  
 
Understanding the relationship between baseline hydration status, functional outcome and the 
potential mechanism for this relationship will elucidate more precise treatments. This work will 
validate objective, continuous markers that could be used to quantify hydration status for use in 
future clinical trials. The results of this and future related studies have the potential to greatly 
impact stroke care by providing data about best fluid management. If beneficial to the acute 
stroke patient, rehydration may offer an inexpensive and globally available adjunct therapy to 
improve functional outcomes and reduce stroke related disability. 
 
Background and importance of this research 
 
Stroke remains a leading cause of adult disability worldwide.1 Yet, there are very few treatments 
with proven impact on clinical outcome, and those therapies are underutilized, often due to 
limited access and lack of a uniform benefit.2  While treatments like tPA and mechanical 
thrombectomy have proven benefit, it is likely that a host of variables contribute to worsened 
stroke severity and recovery despite these treatments. The brain of the stroke patient likely 
requires a finely-tuned physiologic environment to minimize neurologic injury and promote neural 
repair. Dehydration, or more accurately a volume contracted state (VCS) may worsen 
outcomes via alterations in cerebral blood flow, oxygen delivery, or distribution of inflammation. 
This proposal evaluates VCS as an important contributor to early stroke progression and clinical 
outcome. 
 
Dehydration is common at the time of stroke, may increase risk for poor outcome, and is 
modifiable. There is mounting evidence that 36-56% of patients presenting to the hospital with 
acute ischemic stroke have an alteration in volume status as estimated by crude laboratory 
markers.3-7 Furthermore, dehydration, which may actually reflect a VCS, has been hypothesized 
to be an important variable in stroke progression or stroke-in-evolution,4-6,8  with stroke 
progression leading to higher mortality.4,8 Clinicians may be reluctant to aggressively hydrate 
these patients with isotonic intravenous fluids citing risk for worsening hypertension, 
decompensated heart failure, or cerebral edema. Current practice guidelines acknowledge the 




than clinical trial data, but make no recommendation about the diagnostic criteria for 
hypovolemia, nor the timing or duration of treatment.9 Although saline has not been formally 
studied as an active intervention in clinical trials, important observations from the study of other 
interventions provide data on the potential utility of saline. Hemodilution studies such as the 
ALIAS trial, using albumin after acute ischemic stroke, yielded equivocal results,10-13 but 
importantly, this may have been because the control group was given saline, which may 
actually have led to better outcomes in this control group than would have been found were 
there a control group without any fluid therapy. Furthermore, no studies to date have sought to 
investigate dosing or duration of fluid therapy. If demonstrated to have a positive effect on 
stroke outcome, fluid replacement would be a low-cost, readily available treatment. 
 
Hydration status may be especially important during hyperacute therapies. The benefit of 
acute stroke treatments (tissue plasminogen activator tPA and mechanical embolectomy) have 
been variable, with an estimated 33% of recipients achieving good functional outcome 
(measured by modified Rankin Scale (mRS) of 0-1 at 3 months).14,15 The benefit of tPA is likely 
modified by a variety of physiological parameters including baseline platelet activity, renal, and 
hepatic function.16 Hydration status may be another important variable. Hydration could impact 
the effect of these acute therapies via changes in both drug delivery, support of collateral 
circulation to the penumbra, and reduction of drug related side effects. Additionally, hydration 
could play a role in the pharmacodynamics of tPA (e.g. medication’s volume of distribution) and 
clearance, therefore altering the medication’s ability to facilitate revascularization, and may even 
increase side effects. Finally, acute stroke patients who are dehydrated may develop earlier 
ischemic changes on CT scan or other exclusions to tPA therapy, thus contributing to a 
difference in rates of tPA administration. A recent study suggested that dehydration may be an 
important prognostic factor among patients receiving tPA.17 To our knowledge no studies have 
evaluated if dehydration modifies tPA’s ability to improve outcomes among all ischemic stroke 
patients who are within the 4.5 hour treatment window. There have been no studies to date 
exploring the association of dehydration and results of mechanical embolectomy. 
 
Objective markers of clinical hydration status are neither easily available nor validated. 
Thus, the diagnosis of dehydration or a VCS is often inaccurate, subjective, leading to 
variability in clinical practice.18-21 Further there is no validated method to monitor hydration 
status in real time in order to determine endpoints for rehydration therapy on an individualized 
basis. Acute ischemic stroke guidelines do not provide objective definitions of the target 




bedside observation, precise hydration strategies have been challenging to design or study. A 
quantitative surrogate marker of hydration status is useful in the evaluation of a patient’s overall 
volume status.22 In stroke patients, observational studies including our own (see Preliminary 
Studies) using surrogate lab markers suggest that elevated serum BUN, serum osmolarity, 
urine specific gravity, and/or plasma brain natriuretic peptide predict worsened outcomes.3-7,23-
27 These lab measures are commonly utilized in general medical care,28 but require painful 
blood draw and a time lag to receive the results in order to determine the need to change 
therapy. A noninvasive cardiac monitor designed to trend intravascular volume may be one 
solution. 
 
A noninvasive cardiac output monitor may more accurately measure volume status, but 
has not been tested in stroke patients. Traditional means of assessing intravascular volume 
has relied on invasive technologies (pulmonary artery (PA) catheter that requires right heart 
catheterization or measuring cardiac stroke volume variation via continuous cardiac output 
(PiCCOTM) requiring central venous catheter placement for transpulmonary thermodilution).29 
More recently, a non-invasive cardiac output monitoring system based on chest bioreactance 
has been developed and validated against these invasive technologies.30-34 In a prospective 
observational study validating the noninvasive cardiac output monitor (NICOM) against PA 
catheter, correlation between NICOM and PA catheter was strong (r=0.82), and sensitivity for 
detecting directional changes in intravascular volume was 93% with specificity 93% after 
65,888 measurements,35 suggesting that NICOM may indeed serve as a valid method for 
quantifying hydration status continuously and in real time. The NICOM device has not been 
validated in a population of patients with high likelihood of atherosclerosis and 
autoregulatory issues common in the stroke population. Such a measure of hydration that 
avoided painful blood draws and provided real-time data to the clinician could be a benefit to 
the patient in the form of more precise rehydration when needed. 
 
A focus on such physiological disturbances could have an impact on patient outcomes. 




between volume status and poor neurological 
function after stroke. These include changes in 
endothelial function, platelet activity, and 
perfusion with an impact on eventual prognosis.36-
41 In the setting of acute ischemic stroke, cerebral 
perfusion and autoregulation of perfusion are 
disrupted, thus leaving the brain vulnerable to 
ongoing ischemia. 42-43 When perfusion 
mechanisms fail, neuronal death progresses, and 
infarct expansion becomes inevitable.43 VCS may 
reduce cerebral perfusion and hasten the 
progression from penumbra to infarcted tissue 
during acute ischemic stroke.42-44 Success during 
the transition period after acute stroke is likely 
multifactorial and affected by physiological, 
environmental, and psychosocial conditions. We 
adapt Meleis’ transition theory to conceptualize 
the process and guide our research agenda.45 See Figure 1. 
 
 
Conceptualizing the relationship between hydration status and functional outcome. The 
diagnosis of VCS is a clinical one that is based predominantly on bedside observations. We 
suspect that hydration 
could contribute to both 
a change in acute 
treatment benefit and 
participation in 
rehabilitation (e.g. due 
to fatigue). Thus, 
hydration could have 
an effect on functional 
outcome through both 
direct physiological 
mechanisms (change in 
Figure 2. Conceptualizing hydration as a contributing factor within the stroke transition period 
Figure 1. Adaptation of Meleis’ theory of experiencing 




brain perfusion) and indirect mechanisms within the transition period after stroke (fatigue and 
decreased engagement with rehabilitation). See Figure 2 for conceptual framework.  
 
To date, stroke studies have focused on measuring functional outcomes using the 
modified Rankin scale. The modified Rankin scale is a 6 point ordinal scale that describes the 
functional outcome of a patient.48 The scale has been used in the majority of therapeutic stroke 
studies to quantify potential functional benefit.  The scale is easy to use by a variety of 
providers, can be administered over the phone, and has been well validated in stroke patients.  
 
There is a clinical need driving 
the aims that are proposed in this 
study. Specifically, we: 1) 
investigated mechanisms 
underlying the relationship 
between VCS and outcomes 
after acute stroke treatments; 
and 2) identified the feasibility of 
a readily available yet precise 
method for identification of 
altered volume status in the 
stroke patient. See Figure 3. Two mechanisms by which dehydration impacts outcome were 
explored: 1) dehydration (a VCS) modifies the potential benefit from tPA (Aim 1), and/or may be 
associated with the success of mechanical thrombectomy (Aim 2). We measured the feasibility 
of measuring dehydration (VCS) using noninvasive cardiac output monitoring at the bedside of 
hospitalized stroke patients (Aim 3). 
 
Summary: Overarching issues: 
1)  Dehydration or a volume contracted state (VCS) at the time of stroke is common and is 
independently associated with worsened severity and functional outcome.  
2)  The mechanism behind the relationship between dehydration and poor stroke outcome is 
unknown. Further, hydration status may modulate the effect of acute stroke therapies. 
3)  Current rehydration practices after stroke are variable, in part related to the subjective 
method for diagnosing dehydration; benefit of formal rehydration therapies are surprisingly 
understudied. 
Figure 3. Identifying a potential relationship between hydration status and success 
of acute stroke therapy requires measuring hydration & examining outcomes after 




4)  Development of appropriate rehydration strategies would benefit from knowing the 
hydration status of a patient in real time and without invasive and painful procedures (blood 
draws etc.). 
5)  In order to prescribe rehydration therapies accurately we must better understand the 
population at risk. 
 
Combining fundamental knowledge of cerebral blood flow after acute ischemic stroke with 
observations of hydration practices in the clinical setting provides the platform for this study. 
The studies proposed in this application will allow for the development of a pragmatic clinical 
trial of rehydration after acute ischemic stroke with the long-term goal of developing a 




The only interventions for acute ischemic stroke that have been shown to improve outcome (IV 
tPA and mechanical thrombectomy) are not available to a large percentage of the world’s 
population, either due to expense of the treatment or inaccessibility to the necessary technology 
(including imaging). Even in the US, still only an estimated 2-8% of ischemic stroke patients 
receive these interventions due to delay in arrival to a treating center after onset of 
symptoms.49-52 Furthermore, outcome after these interventions is still variable, with many 
individuals not having the anticipated benefit despite receiving these therapies. Rehydration 
with intravenous saline (0.9% sodium chloride) is ubiquitously available and inexpensive; the 
proposed study could lay important groundwork for a clinical trial directly testing the utility of IV 
saline in a large population of acute ischemic stroke patients. If fluid replacement in volume 
contracted patients improves outcome without increasing adverse events, it would 
provide the first effective stroke treatment that is globally available, widely accessible, 
and cost effective. However, this simple intervention has not been sufficiently studied to guide 
specific recommendations of when and how to rehydrate stroke patients.22  
 
The overall goal of this study is to determine the potential causes of poor functional 
outcome in patients with a VCS, and to test a continuous quantitative method for 
evaluating VCS for potential use in future clinical trials. To evaluate the causes of poor 
outcome, we will 1) test the relationship between VCS and efficacy of tPA in a retrospective 
observational study, 2) compare the percentage of patents who achieve successful 




prospectively measure hydration status using a noninvasive cardiac output monitor. This 
hypothesis will be tested in a consecutive series of acute ischemic stroke patients admitted to a 
single comprehensive stroke center. 
 
PRELIMINARY STUDIES 
We have completed several foundational studies to support the hypothesis that volume 
contraction is frequent in acute ischemic stroke patients using indirect laboratory markers 
and may directly relate to worse clinical outcome after stroke. 
 
1.  VCS and hemispatial neglect in stroke:53 A retrospective review of 201 patients with non-
dominant hemispheric ischemic stroke demonstrated that 65% of patients had elevated serum 
BUN/creatinine ratio > 15, the presence of which was associated with a 4-fold higher odds of 
severe neglect syndromes (OR 4.1, 95% CI 1.2, 14.4), independent of infarct size. Using a 
composite definition for VCS of elevated BUN/creatinine > 15 and urine specific gravity > 1.010, 
57% of patients were volume contracted at the time of hospital admission for acute ischemic 
stroke. Further, all patients with 
elevated urine specific gravity 
had severe neglect syndromes 
(p=0.06) (Figure 4), defined by 
Z scores of -2 or less on at 
least two of three neglect tests, 
compared to normal controls. 
These data support our 
hypothesis that many acute 
stroke patients are volume 
contracted at the time of 
stroke and that clinical 





2. VCS and short term outcomes:7 We examined the relationship between VCS and short 
term outcome at the time of hospital discharge in an observational study of 126 acute ischemic 
stroke patients. VCS was 
evaluated at the time of 
presentation for acute 
ischemic stroke, defined as 
BUN/creatinine ratio>15 and 
urine specific gravity>1.010 
(found in 44% of patients), 
and NIHSS was documented 
at time of admission and 
discharge; the difference was 
calculated. Of the patients in 
a VCS, 42% were in the 
worst quartile as compared 
with 17% of the euvolemic group (p=0.02; Figure 5). Relative volume depletion remained a 
significant predictor of having the worst NIHSS change after adjustment for age, admission 
glucose, and baseline MRI lesion volume (OR=4.34, 95% CI 1.75-10.76). These data support 
the hypothesis that VCS may affect longer term outcomes and could provide a potential 
biomarker to track response to rehydration therapy.  
 
Summary of preliminary results: Preliminary data show that a lab defined volume contracted 
state (BUN/creatinine ratio > 15) is common at the time of stroke, and patients with a VCS at 
the time of stroke may have worse outcomes. The issue is that current methods of detecting a VCS 
are invasive, potentially painful, and results are not available to providers in real-time in order to efficiently 
treat the condition. Additionally, there may be an interaction between VCS and acute stroke 
treatments making more precise and efficient diagnosis of VCS more of a clinical priority. 
Taken together, we will evaluate the relationship between VCS and outcomes after acute stroke 
treatments. Additionally, we will test the feasibility of NICOM measurement of VCS in a series of 
hospitalized stroke patients and correlate results with indirect markers of VCS (BUN/creatinine ratio). 
Should VCS be associated with worse outcome after treatment of acute stroke, these data could 
suggest the possibility that VCS is a modifiable risk factor, amenable to low cost and broadly 
available intervention. The data derived from this proposal will provide foundational data for 




References: Chapter 1 
 
1. Mozaffarian, D, Benjamin, EJ, Go, AS, Amett, DK, Blaha, MJ, Cushman, M, de Ferranti, S, 
Després, J, Fullerton, HJ, Howard, VJ, Huffman, MD, Judd, SE, Kissela, BM, Lackland, DT, 
Lichtman, JH, Lisabeth, LD, Liu, S, Mackey, RH, Matchar, DB, McGuire, DK, Mohler, ER, 
Moy, CS, Muntner, P, Mussolino, ME, Nasir, K, Neumar, RW, Nichol, G, Palaniappan, L, 
Pandey, DK, Reeves, MJ, Rodriguez, CJ, Sorlie, PD, Stein, J, Towfighi, A, Turan, TN, Virani, 
SS, Willey, JZ, Woo, D, Yeh, RW, Turner, MB; on behalf of the American Heart Association 
Statistics Committee. Heart Disease and Stroke Statistics – 2016 Update. A Report from the 
American Heart Association. Circulation. 2015; 132:e1-324.  
2. Powers, WJ, Derdeyn, CP, Biller, J, Coffey, CS, Hoh, BL, Jauch, EC, Johnston, JC, Johnston, 
SC, Khalessi, AA, Kidwell, CS, Meschia, JF, Ovbiagele, B, Yavagal, DR. 2015 AHA/ASA 
Association focused update of the 2013 guidelines for the early management of patients with 
acute ischemic stroke regarding endovascular treatment. Stroke. 2015; 46: 3024-3039. 
3. Rowat, A, Graham, C, Dennis, M. Dehydration in hospital admitted stroke patients: detection, 
frequency and association. Stroke. 2012; 43:857-859.  
4. Lin, LC, Fann, WC, Chou, MH, Chen, HW, Su, YC, Chen, JC. Urine specific gravity as a 
predictor of early neurological deterioration in acute ischemic stroke. Medical Hypotheses. 
2011; 77:11-14.  
5. Lin, LC, Yang, JT, Weng, HH, Hsiao, CT, Lai, SL, Fann, WC. Predictors of early clinical 
deterioration after acute ischemic stroke. American J Emerg Med. 2011; 29(6):577-581.  
6. Lin, LC, Lee, JD, Hung, YC, Chang, CH, Yang, JT. BUN/creatinine ratio-based hydration for 
preventing stroke-in-evolution after acute ischemic stroke. American Journal of Emergency 
Medicine. 2014; 32:709-712.  
7. Bahouth, MN, Gaddis A, Hillis AE, Gottesman, RF. A pilot study of volume contracted state 
and hospital outcome after stroke. Neurol Clin Pract. 2018; 8:1-6.  
8. Sumer, M, Ozdemir, I, Erturk, O. Progression in acute ischemic stroke: frequency, risk factors, 
and prognosis. J Clin Neurosci. 2003; 10(2):177-180.  
9. Jauch EC, Saver JL, Adams, Bruno, A, Connors, JJ, Demaerschalk, BM, Khatri, P, McMullan, 
PM, Qureshi, AI, Rosenfield, K, Scott, PA, Summers, DR, Wang, DZ, Wintermark, M, Yonas, 
H, on behalf of the American Heart Association Stroke Council, Council on Cardiovascular 
Nursing, Council on Peripheral Vascular Disease, and Council on Clinical Cardiology. 




healthcare professionals from the American Heart Association/American Stroke Association. 
2013; 44:870-947.  
10. Ginsberg, MD, Palesch, YY, Martin, RH, Hill, MD, Moy, CS. The albumin in acute stroke 
(ALIAS) multicenter clinical trial: safety analysis of part 1 and rationale and design of part 2. 
Stroke. 2011; 42:119-127.  
11. Ginsberg, MD, Palesch, YY, Hill, MD, Martin, RH, Moy, CS, Barsan, WG, Waldman, BD, 
Tamariz, D, Ryckborst, KJ; ALIAS and Neurological Emergencies Treatment Trials (NETT) 
Investigators. High-dose albumin treatment for acute ischemic stroke (ALIAS) part 2: a 
randomized, double-blind, phase 3, placebo-controlled trial. Lancet Neurology. 2013; 
12:1049-1058.  
12. Bayer, AJ, Pathy, MS, Newcombe, R. Double-blind randomized trial of intravenous glycerol in 
acute stroke. Lancet. 1987; 1(8530):405-408.  
13. Rudolf, J, HES in Acute Stroke Study Group. Hydroxyethyl starch for hypervolemic 
hemodilution in patients with acute ischemic stroke: a randomized, placebo-controlled phase 
II safety study. Cerebrovascular Dis. 2002; 14(10):33-41. 
14. National Institute of Neurological Disorders (NINDS) and Stroke rt-PA Stroke Study Group. 
Tissue plasminogen activator for acute ischemic stroke. NEJM. 1995;333(24): 1581-1587.  
15. Hacke, W, Kaste, M, Bluhmki, E, Brozman, M, Davalos, A, Guidetti, D, Larrue, V, Lees, KR, 
Medeghri, Z, Machnig, T, Schneider, D, vonKummer, R, Wahlgren, N, Toni, D. Thrombolysis 
with alteplase 3-4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359:1317-1329. 
16. Demchuk, AM, Tanne, D, Hill, MD, Kasner, SE, Hanson, S, Grond, M, Levine, SR. Predictors 
of good outcome after intravenous tPA for acute ischemic stroke. Neurology. 2001; 57(3): 
474-480.  
17. Wu, FF, Hung, YC, Tsai, YH, Yang, JT, Lee, TH, Liow, CW, Lee, JD, Lin, CJ, Peng, TI, Llin, 
LC. The influence of dehydration on the prognosis of acute ischemic stroke for patients treated 
with tissue plasminogen activator. BMC Cardiovasc Disord. 2017;17:154  
18. Mange, K, Matsuura, D, Cizman, B, Soto, H, Ziyadeh, FN, Goldfarb, S, Neilson, EG. Language 
guiding therapy: the case for dehydration versus volume depletion. Annals of Internal 
Medicine. 1997; 127(9):848-853.  
19. Bhave, G and Neilson. Volume depletion versus dehydration: how understanding the 




20. Armstrong, LE, Johnson, EC, McKenzie, AAL, Munoz, CX. Interpreting common hydration 
biomarkers on the basis of solute and water excretion. European Journal of Clinical Nutrition. 
2013; 67:249-253. 
21. Armstrong, LE. Assessing hydration status: the elusive gold standard. Journal of the American 
College of Nutrition. 2007; 26:575S-584S.  
22. Visvanathan, A, Dennis, M, Whiteley, W. Parenteral fluid regiments for improving functional 
outcome in people with acute stroke. Stroke. 2016; 47:e6-e7.  
23. Schrock, JW, Glasenapp, M, Drogell, K. Elevated blood urea nitrogen/creatinine ratio is 
associated with poor outcome in patients with ischemic stroke. Clinical Neurology and 
Neurosurgery. 2012; 114:881-884.  
24. Bhalla, A, Sankaralingam, S, Dundas, R, Swaminathan, R, Wolfe, CD, Rudd, AG. Influence 
of raised plasma osmolality on clinical outcome after acute stroke. Stroke. 2000; 31:2043-
2048.  
25. Rodriguez, GJ, Cordina, SM, Vazquez, G, Suri, MF, Kirmani, JF, Qureshi, AI. The hydration 
influence on the risk of stroke (THIRST) study. Neurocritical Care. 2009; 10:187-194.  
26. Shibazaki, K, Kimura, K, Okada, Y, Iguchi, Y, Uemura, J, Terasawa, Y, Aoki, J. Plasma brain 
natriuretic peptide as an independent predictor of in-hospital mortality after acute ischemic 
stroke. Internal Medicine. 2009; 48:1601-1606.  
27. Beier, K, Eppanapally, S, Bazick, HS, Chang, D, Mahadevappa, K, Gibbons, FK, Christopher, 
KB. Elevation of blood urea nitrogen is predictive of long-term mortality in critically ill patients 
independent of ‘normal’ creatinine. Crit Care Med. 2011; 39:305-313.  
28. Hollenberg, SM, Ahrens, TS, Annane, D, Astiz, ME, Chalfin, DB, Dasta, JF, Heard, SO, Martin, 
C, Napolitano, LM, Susla, GM, Totaro, R, Vincent, JL, Zanotti-Cavazzoni, S. Practice 
parameters for hemodynamic support of sepsis in adult patients. Critical Care Medicine. 2004; 
32(9):1928-1948.  
29. Harvey, S, Harrison, DA, Singer, M, Ashcroft, J, Jones, CM, Elbourne, D, Brampton, W, 
Williams, D, Young, D, Rowan, K. Assessment of the clinical effectiveness of pulmonary artery 
catheters in management of patients in intensive care (PAC-Man): a randomized controlled 
trial. Lancet. 2005; 366:472-477.  
30. Thiele, RH, Bartels, K, Gan, TJ. Cardiac output monitoring: a contemporary assessment and 
review. Critical Care Medicine. 2015; 43:177-185.  
31. Kalantari, K, Chang, JN, Ronco, C, Rosner, MH. Assessment of intravascular volume status 




32. Squara, P, Cecconi, M, Rhodes, A, Singer, M, Chiche, JD. Tracking changes in cardiac output: 
methodological considerations for the validation of monitoring devices. Intensive Care 
Medicine. 2009; 35:1801-1808.  
33. Marik, PE. Noninvasive cardiac output monitors: a state of the art review. Journal of 
Cardiothoracic and Vascular Anesthesia. 2013; 27(1):121-134. 
34. Keren, H, Burkhoff, D, Squara, P. Evaluation of a noninvasive continuous cardiac output 
monitoring system based on thoracic bioreactance. American Journal Physiol Heart Circ 
Physiology. 2007; 293:H583-589.  
35. Squara, P, Denjean, D, Estagnasie, P, Brusset, A, Dib, JC, Dubois, C. Noninvasive cardiac 
output monitoring (NICOM): a clinical validation. Intensive Care Med. 2007; 22:1191-1194.  
36. Baskurt, O and Meiselman, HJ. Iatrogenic hyperviscosity and thrombosis. Seminars in 
Thrombosis and Hemostasis. 2012; 38; 8:854-864.  
37. Lip, GYH, Blan, AD, Farooqi, IS, Zarifis, J, Sagar, G, Beevers, DG. Sequential alterations in 
haemorheology, endothelial dysfunction, platelet activation and thrombogenesis in relation to 
prognosis following acute stroke: the West Birmingham stroke project Blood Coagulation and 
Fibrinolysis. 2002; 13:339-347.  
38. Wiseman, S, Marlborough, F, Doubal, F, & Webb, DJ. Blood markers of coagulation, 
fibrinolysis, endothelial dysfunction and inflammation in lacunar stroke versus non-lacunar 
stroke and non-stroke: systemic review and meta-analysis. Cerebrovascular Diseases. 2014; 
37:64-75.  
39. Widlansky, ME, Gokce, N, Kennedy, JF, Vita, JA. The clinical implications of endothelial 
dysfunction. J Am Coll Cardiol. 2003; 42:1149-1160.  
40. Lu, D and Kassab, GS. Role of shear stress and stretch in vascular mechanobiology. J. R. 
Soc. Interface. 2011; 8:1379-1385.  
41. Gonzalez-Alonso, J, Mora-Rodriguez, R, Below, PR, Coyle, EF. Dehydration reduced cardiac 
output and increases systemic and cutaneous vascular resistance during exercise. Journal of 
Applied Physiology. 1995; 79:1487-1496. 
42. Stevenson, SF, Doubal, FN, Shuler, K, & Wardlaw, JM. A systematic review of dynamic 
cerebral and peripheral endothelial function in lacunar stroke versus control. Stroke. 2010; 
41:e434-3442.  
43. Astrup J, Seisjo BK, Symon L. Thresholds in cerebral ischemia – the ischemic penumbra. 




44. Anderson, TJ, Uehata, A, Gerhard, MD, Meredith, IT, Knab, S, Delagrange, D, Lieberman, 
EH, Ganz, P, Creager, MA, Yeung, AC, Selwyn, AP. Close relation of endothelial function in 
human coronary and peripheral circulations. J Am Coll Cardiol. 1995; 26:1235-1241.  
45. Meleis, A.I. Transitions Theory. Springer; New York 2010 
46. Katzan, IL and Lapin, B. PROMIS GH (Patient-reported outcomes measurement information 
system global health) scale in stroke. Stroke. 2018; 49: 147-154 
47. Katzan, IL, Thompson, N, Uchino, K. Innovations in stroke: the use of PROMIS and NeurQOL 
scales in clinical stroke trials. Stroke. 2016; 47(2):e27-30. 
48. Fearon, P, McArthur, KS, Garrity, K, et al. Prestroke modified Rankin stroke scale has 
moderate interobserver reliability and validity in an acute stroke setting. Stroke; 2012: 43(12): 
3184-3188. 
49. Kleindorfer, D, Lindsell, CJ, Brass, L, Koroshetz, W, Broderick, JP. National US estimates of 
recombinant tissue plasminogen activator use: ICD9 codes substantially underestimate. 
Stroke. 2008; 39(3): 924-928  
50. Kleindorfer, D, Xu, Y, Moomaw, CJ, Khatri, P, Adeoye, O, Hornung, R. US geographic 
distribution of rt-PA utilization by hospital for acute ischemic stroke. 2009; 40(11):3580-3584.  
51. Moradiya, Y, Crystal, H, Valsamis, H, Levine, SR. Thrombolytic utilization for ischemic stroke 
in US Hospitals with neurology residency programs. Neurology. 2013; 81(23):1986-1995.  
52. Opeolu, A, Hornung, R, Khatri, P, & Kleindorfer, D. Recombinant tissue-type plasminogen 
activator use for ischemic stroke in the United States: A doubling of treatment rates over the 
course of 5 years. Stroke. 2011; 42(7):1952-1955.  
53. Bahouth, MN, Bahrainwala Z, Hillis AE, Gottesman RF. Dehydration status is associated with 







Chapter 2. Review of research* 
*This chapter has been published: 
Bahouth, MN, Gottesman, RF, Szanton, SL. Primary ‘dehydration’ and acute stroke: a systematic 
research review. Journal of Neurology. 2018; https://doi.org/10.1007/s00415-018-8799-6 
 
Background and Purpose: Hydration status at the time of stroke has been acknowledged as 
an important determinant in early stroke recovery. However, the diagnosis of dehydration, or 
more accurately, a volume contracted state, at the time of stroke is challenging since there are 
currently no consensus diagnostic criteria. In this systematic review, we gather the available 
evidence about diagnosis and treatment of dehydration after stroke.  
 
Methods: Studies of hospitalized ischemic stroke patients that reported rates of dehydration 
from January 1997 to March 2017 were screened for inclusion via a systematic search of 
PubMed, CINAHL, Cochrane and Scopus using keywords hydration, dehydration, hemodilution, 
viscosity, volume status and thirst.  
 
Results: Twenty-five studies of 8699 acute stroke patients were included. Nineteen studies 
reported on the diagnostic approach to dehydration.  Findings are synthesized into the three 
main categories of available research including studies that specify: 1) biological mechanisms 
using animal models to investigate the relationship between dehydration and stroke; 2) 
measures of dehydration in the acute human stroke population; 3) rehydration therapies after 
stroke; and 4) outcomes after stroke in dehydrated patients. 
 
Conclusions: We found considerable variation in terminology specific to hydration status, 
diagnostic approach to dehydration, and few prospective studies of treatment strategies with 
varying results. This review supports the need for consensus development of operational 
diagnostic criteria, standardization of language, and the opportunity for prospective study of 




Introduction: Dehydration is a major contributor to morbidity and mortality in the elderly.1 Thirst 
drive decreases with age, leaving the older population vulnerable to high rates of dehydration.2 
A large percentage of stroke patients are dehydrated at the time of stroke and appear to have 
worsened functional outcomes.1-3 Current acute stroke guidelines recommend,  rehydration for 
patients who are dehydrated.4 However, implementation of those guidelines have been 
challenging because definitions of dehydration are subjective, and rehydration 
recommendations are imprecise.5 Additionally, the variety of terms used to describe alterations 
in hydration status in the clinical arena, further complicates and  impedes research in the area of 
dehydration and stroke.6 
 
Dehydration is both common at the time of stroke and a frequent complication of stroke due to 
swallowing dysfunction.3 Although clinical diagnostic approaches involving bedside assessment 
of hydration status are available, identifying dehydration in stroke patients remains particularly 
challenging for several reasons. The clinical presentation of dehydration in patients with stroke 
may be nonspecific, not perceived as a priority by the clinical team, or reliant on invasive 
techniques for objective measurement of dehydration. Further, identification of thirst in the 
stroke patient may be masked by altered mental status, alteration in language function, or 
diminished thirst mechanisms common in the elderly or patients with hypothalamic circuit 
disruption. Under-treatment of altered hydration status may have negative consequences on the 
patient’s recovery. Therefore, it is especially important for stroke providers to have clear and 
evidence-based parameters to guide patient care in this area. 
 
Dehydration might adversely affect the acute stroke patient in several ways: 1) reduced brain 
perfusion,7 2) increased fatigue;8 3) impaired neuroplasticity.9 During the early stroke recovery 
period, autoregulatory systems are impaired, leaving the brain vulnerable to blood viscosity and 
pressure changes that could further injure the area already compromised by decreased oxygen 
and nutrients. Next, the functional consequences of dehydration during the early stroke recovery 
period could include: increased rates of delirium, poor concentration, increased fatigue, or 
positional hypotension. These early functional consequences may be crucial since 
neuroplasticity is thought to peak in the first several weeks after stroke so engagement in 
physical therapy during this limited period is critical.10  
 
Our research team sought to understand the state of the science in the area of dehydration and 




hydration treatments in hospitalized stroke patients, and identify gaps in the scientific literature. 
We present the synthesis of research findings of clinical studies that evaluate hydration 
measurement strategies, clinical studies of rehydration techniques, and animal research that 
underscore the biological rationale for hydration and stroke research.  
 
Methods:  
Search and data abstraction methods: Literature for this research summary was systematically 
identified via Pubmed, CINAHL, Cochrane, and Scopus using the following search terms: 
“dehydration,” “dehyd,” “hydration,” “blood viscosity,” “volume contraction,” “hypertonicity,” 
“thirst,” “hemodilution,” “haemodilution,” “stroke” [Mesh] from January 1997- March 2017. We 
selected 1997 as the start year to reflect a major change in acute stroke care with the advent 
and approval of thrombolytic therapy for acute stroke.11 Additional literature was identified by 
reviewing bibliographies of each publication identified through the initial search. Classic 
research studies prior to the twenty year date range were reviewed with the purpose for 
developing knowledge about physiological mechanisms behind dehydration and stroke. Only 
research published in English was reviewable by the study team. Studies were included if they 
were specific to hydration status in hospitalized patients with first time ischemic stroke. We 
excluded research about dehydration due to swallowing difficulties, as well as dehydration 
occurring in the chronic (late) phase of stroke in order to maintain focus on the time period of 
interest (the immediate post-stroke period).  
Quality assessment was performed using the Quality Assessment tool for quantitative studies.12 
Using this pre-specified tool, the reviewer (MB) abstracted and scored data from eligible studies 
including assessment of study design, and potential bias. An overall score was assigned to 
each individual study resulting in ratings of (1) strong, (2) moderate, or (3) weak. 
 
Results: 
Study selection and rationale: Using our above search strategy and manual searches of 
bibliographies, we identified 3665 potential publications for inclusion. Once narrowed based on 
removal of duplications, our language and exclusion criteria, 190 publications were screened 
eventually yielding 29 original research studies for inclusion (25 human,3,13-36 and 4 animal37-40) 
plus 2 relevant Cochrane reviews.41, 42 See Figure 1. Of note, there were no qualitative research 
publications in the area of hydration status and stroke. Both human and animal research is 
included in this review to give a comprehensive picture of the state of the science. We narrowed 




stroke patients in order to target a more homogenous population. Ischemic and hemorrhagic 
strokes were included though patients with subarachnoid hemorrhage were excluded based on 
the unique aspects of post-aneurysm fluid management.  
 
Study characteristics: Twenty-five studies of 8699 acute stroke patients were included.3,13-36 
Nineteen of those studies focused on diagnostic approaches to dehydration in this 
population3,13-29,36 and five researched potential treatments of the condition.30-34 The majority 
(90%) of included studies were conducted in Asia, Europe, and the Middle East.13-27, 29-36 The 
remaining three studies were completed in the United States.27,35,36 In general, patients included 
in these studies were older (mean age > 60 in all but one study). Women were well represented 
in all studies. Two studies reported race characteristics.27,36  
 
Stroke confirmation for inclusion in studies: Radiologic confirmation of stroke with MRI (gold 
standard) was reported in 2/25 (8%) studies.16, 28 Severity of the stroke using standard measure 
of the NIH stroke scale score was reported in 16/25 (64%) of studies. Stroke severity was mild 
to moderate with average baseline NIH stroke scale scores, among those studies where it was 
provided, ranging from 4-13.15, 16, 19, 27, 30-33, 35,36 The study by Dharmasaroja and colleagues was 
the exception since that study was designed to include only patients with severe stroke (mean 
NIH stroke scale score was 20).30 Several clinical outcome measures were used in the 13 
studies reporting clinical outcomes. Modified Rankin scores, a score of functional outcome that 
is used in most stroke clinical trials,43 was reported in four studies. Barthel lndex, a well-
validated score of level of independence in activities of daily living,44, 45 was used in 3 studies. 
Final outcome assessment times ranged from three days to three months post-stroke. 
 
Studies measuring dehydration: In the 24 human studies, a variety of terms were used to 
describe hydration status. Abnormality in hydration was called “dehydration” in most cases, 
though other authors used volume depleted, volume contracted, fluid imbalance, or increased 
urea to creatinine ratio. Table 1 summarizes the nineteen studies (79%) that specifically 
addressed diagnostic approaches to dehydration in this population.3,13-36 The majority used 
objective indirect diagnostic criteria: 18/20 (90%) used laboratory values,13-16,18-30, 35,36 one study 
used weight,24 and one used nursing clinical assessment.25 Overall, rates of dehydration in the 
acute stroke population ranged from 29-70% using a variety of measurement techniques.13, 16, 19, 
20, 21, 24-27, 35,36 The substantial heterogeneity observed was not explained by comparing 




blood urea nitrogen to creatinine ratio (BUN/Cr) which was used in 12 studies, though three 
different thresholds to define ‘dehydration’ were used (BUN/Cr ratios of > 15, > 20, > 25). Serum 
osmolality, a more direct marker of hydration status, was used in five studies. Of the twelve 
studies reporting patient outcomes, ten (83%) reported worse clinical outcomes in dehydrated 
stroke patients.3, 14, 15, 17, 19-24, 26-28 A notable gap is that none of the studies of dehydration in the 
post-stroke patient measured the patient experience of thirst and only one used change in 
weight to measure hydration status.24 One technology-based assessment of bioimpedence to 
measure hydration yielded negative results when trying to validate the tool against standard 
measures of dehydration.29  
 
Studies evaluating treatments of dehydration: Two relevant comprehensive Cochrane reviews of 
therapeutic approaches to rehydration using parenteral fluids (12 studies, 2351 participants) and 
hemodilution (21 studies, 4174 participants) in the acute stroke population were published in 
2015 and 2014 respectively. Since that time, five studies of rehydration in stroke have been 
published: 2 quasi-experimental, two historical case control, and one cohort study. See Table 2. 
Of those, 4/5 (80%) suggest improvement in function and lower death rates with rehydration.31-34 
One study suggested increased cerebral edema in patients with large stroke who receive higher 
volumes of rehydration.31 Though only a single study, with moderate biases due to the 
retrospective study design, this potential complication is of substantial clinical relevance as 
cerebral edema is a primary concern after stroke and contributes to stroke mortality.  
 
Biological Models: When considering the biological rationale for a potential relationship between 
hydration status and stroke outcome, one classic human study46 and four studies using animal 
models were identified during our systematic literature search.37-40 A classic paper published in 
1974 by Ott and colleagues investigated the trends in hydration using blood viscosity.46 They 
studied 50 patients with cerebral angiogram to assess atherosclerosis near the time of stroke 
and found that acute stroke patients with higher burden of atherosclerotic disease demonstrated 
high blood viscosity. Researchers surmised that hydration status in this cohort of patients with 
mean age of 70 may be contributing to stroke.46 On this platform, animal studies have been 
conducted to investigate this phenomenon.37-40 These are well designed studies using a variety 
of animal models of induced stroke. In all four studies, hydration status has been associated 
with worse outcome.37-38 Most compelling is the finding that supported access to food and water 
was independently associated with decreased mortality regardless of infarct size in a series of 





Summary of study outcomes: Taken together, this systematic review suggests that there 
appears to be a relationship between hydration status and poor outcome after stroke in both 
animal and human studies. The language used to describe hydration status within this body of 
research was imprecise but taken together underscore an important clinical issue for which best 
practice is still largely unknown. The studies provide critical information, though the majority 
have weak to moderate designs with limitations in the ability to generalize findings due to lack of 
diversity among included participants. Thus far, Asian populations and Caucasians appear to 
demonstrate the same relationship between hydration status and functional outcome after 
stroke, but extending the diversity of the study populations is very important especially when 
using lab based definitions to describe hydration status.  
 
All clinical studies of dehydration measures at the time of stroke reported worse clinical 
outcomes in volume contracted patients. Studies of interventions or comparisons of rehydration 
approaches yielded varying results. One study identified increased rates of cerebral edema in 
patients with large stroke who received > 1.6L of fluids per day after stroke. Though a very 
concerning and clinically relevant concern, small sample size and retrospective design limit 
generalizability of these findings. Thus, further work will be needed to better understand this 
potential hazard as formalized therapies are being created. Studies by Lin and colleagues used 
a more formalized strategy to rehydrate stroke patients with isotonic saline at specified rates 
and demonstrated lower rates of stroke in evolution (p=0.026),32 lower rates of infection 
(p=0.018),33 and shorter lengths of hospital stay (p=0.001).33 Thus, there is an opportunity to 
further investigate treatment strategies specific to rehydration and the impact on patient level 
outcomes. Future studies will require careful monitoring of patients with large territory stroke for 
complications related to cerebral edema as an important endpoint of measure. 
 
Discussion: Although these studies have laid the biological foundations and groundwork, 
further work is needed in the area in order to determine the relationship between hydration 
status and functional outcome after stroke. We provide recommendations for future investigation 
based on both the knowledge and limitations of these research studies. 
 
Recommendation 1 – a single, objective measure of dehydration should be validated and 




The diagnosis of dehydration remains mostly subjective leaving a relative lack of a gold 
standard for objective clinical diagnosis of dehydration. Validation of such markers are ongoing. 
To date, BUN/Creatinine ratio has been used in stroke hydration studies and yielded the most 
consistent result in terms of stroke outcome. Elevation of this biomarker (suggesting abnormality 
in hydration status) is common, appears to correlate with worse functional outcome, and 
appears modifiable with intravenous fluids. The most common threshold for abnormality is 
BUN/creatinine ratio > 15. When using BUN/creatinine ratio as an indirect biomarker, we 
choose terminology specific to alteration in volume status (or a volume contracted state when 
the BUN creatinine ratio is > 15). BUN/creatinine likely reflects intravascular volume depletion 
and not true dehydration (no alteration in serum sodium). It is a broadly available lab test 
worldwide and obtained commonly at the time of stroke care. One weakness in selecting the 
BUN/ratio as a biomarker is that it requires painful blood draw which should be considered when 
performing serial assessment. Additionally, the time lag between lab draw and receipt of an 
actionable result leaves room for additional novel technologies to guide rehydration therapy 
more precisely. Despite these potential limitations, BUN/creatinine ratio > 15 has been used 
most commonly in stroke hydration research and appears to be a reasonable choice for use in 
future research specific to hydration and stroke outcome. 
 
Recommendation 2 – research studies including more racially diverse populations are 
needed. 
Because muscle mass and therefore creatinine may differ across gender and ethnic groups, it is 
important to include studies from diverse cohorts.  In addition, stroke rates are higher in African 
American and Hispanic populations than caucaisans46 and therefore the effect of race is a 
notable gap in the current literature when considering hydration status and stroke outcome. 
Prospective studies in the United States would be helpful in this area to allow recruitment of 
underrepresented populations. Study of the relationship between race, hydration status and 
stroke outcome is severely lacking and will be critical to individualizing care to the stroke 
population. 
 
Recommendation 3. Exploration of the mechanistic link between hydration status and 
stroke outcome should be pursued 
The majority of the studies reviewed did not include MRI confirmed stroke thus leaving some 
question of the homogeneity of the study sample. It will be important to include only those 




hydration status on outcome. To the recovering stroke patient, detrimental effects of altered 
hydration status may come in a variety of forms: reduction of cerebral perfusion, exposure to 
secondary complications such as delirium and positional orthostasis, alteration in medication 
metabolism, and lethargy contributing to decreased engagement in rehabilitative therapies. 
Additionally, homeostasis specific to volume status may benefit subjective states of well-being 
that could be measures with patient reported outcomes. A better understanding of the 
mechanistic link between hydration and stroke outcome will help to identify improved outcome 
measures as well as potential interventions for this population who remain at high risk for 
disability.  
 
Recommendation 4. Prospective studies should standardize an approach to measuring 
hydration status, and to choosing relevant functional outcomes 
This research synthesis underscores the need to include functional outcome measures such as 
quantitative measures of function, activities of daily living, and mortality. Stroke studies should 
include baseline objective markers of severity in order to adjust for this variable and create more 
robust statistical models as outcomes are interpreted. Complications such as cerebral edema 
and collateral vessel development will be equally important measures to better understand the 
impact of dehydration on neuroplasticity. The majority of studies included information about 
functional outcome at the time of hospital discharge and at the three month follow-up time point 
and future studies should attempt to standardize these time points for evaluation for better 
comparison. Lacking in the current body of literature are measures of patient experience, such 
as dehydration-induced fatigue. These markers of patient engagement in restorative therapies 
may inevitably play a role in patient outcome and stroke related disability. 
 
Conclusions: Dehydration is generally considered a sign of illness with severity ranging from 
mild to severe. While there has been substantial research in the area of dehydration and stroke 
recovery, there is much work to be done specific to quantifying dehydration and providing 
treatment to resolve dehydration. This work can be rapidly translated into clinical practice to 
impact patient care and stroke related disability. Rehydration therapy would be a low cost and 
broadly available therapy for stroke patients if proven to benefit outcomes. It is a therapy that 
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More dehydration in subjects > 80 yo 
(p=0.02) 
NR 3 High BUN/creat = more common 
cardioembolic stroke (p=0.02) 
 
Limitations: small sample; retrospective; 
ICD9 diagnoses; generalizability (Japanese 













48h BUN/Cr > 15 and 





More elevated BUN/creatinine ratio in 
subjects with severe neglect compared to 
those without severe n neglect (23 vs 17 
respectively; p=0.0003) 













N NR 24h Plasma osmolality NR Survival 3 mo Mean admission pOsm higher in patients 
w (300 v 293; p < 0.0001) 
BI 3 70% hydrated orally; 30% hydrated 
intravenously 
 












24 h BUN/Cr > 15; 







BUN/Creat >15 and Urine SG > 1.010 
independent risk for neurological 
worsening 
NR 2 (END > 3 pt change NIHSS; 3d) – All with 
END were MCA territory strokes 
 
645 with END had edema 










3d BUN/Cr > 15 70% Collateral 
development 
Dehydration had a negative impact on 
collateral development within 3 days 
from stroke (p=0.001) 
 
Mean time stroke onset to MRI 23h 
mRS 3 ICC 0.924 – high interrater reliability 
assessing collaterals 
 
No significant difference in functional 



















Percent of patients who were dehydrated 
worsened at hospital discharge (55% v 
66% respectively) 
mRS 3 54% of cohort African American 
 
Time from stroke onset to hospitalization 
was not reported; likely secondary 


















Not specified Not specified NR Death 
(hospitalization 
and 3 months) 
BUN/Creat 20.8 v 12.7 (died v survived 
hospitalization, p < 0.001) 
 
BUN/Creat 17.4 v 12.5 (died vs survived 
3 mo, p= 0.007) 














2 weeks Viscosity NR Trend in 
viscosity stroke 
v control 
Baseline viscosity in small vessel stroke: 
5.4 v 4.7 (p < 0.01) 
 
Viscosity decreased at 1 week (IVF); 
Viscosity increased at 2 weeks (no IVF) 
 
BUN/Creat ratio did not change over the 
course of lab draws 
NR 3 Trend in viscosity; no report of how much 
intravenous fluid administered though 
statement made that viscosity trends are 
related to rehydration 









N 8  
 
Ischemic  




(> 3 pt change 
NIHSS; 3d) 
Stroke severity: NIHSS  (SIE = 9.6; No 
SIE = 7.3) 
 
Dehydration -> 3x more likely to have 
SIE (95% CI, 1.36-7.62, p=0.008) 
 
30/194(15%) had SIE  













 Urine specific 





(> 3 pt change 
NIHSS; 3d) 
Dehydrated group = 2.78 times more 
likely to develop SIE (95% CI, 1.1-6.96, 
p=0.030) 
NR 3 **NOTE THAT 196 of the cohort were 

























Dehydrated group: worse median 
NIHSS (5 v 4; p< 0.001);  
higher infection (p=0.006)  
longer LOS;  





2 Large sample size based on ICD9 codes – 
both stroke types 
 
Difference in outcome not clinically 
meaningful; Broad definition of infection 
 
Excluded “high admission costs” patients 
 




















NR Mortality High ddimer in patients who died though 
not significant (p=0.08) 
6mo 2 Multiple hematological measures evaluated 
and trended 
 
Restricted to subjects < 75 years old 
 
Outcomes of death only 




NR 15 79 
 
NR 






NR BI; Good versus 
Bad outcome 




3 Greater reduction in s osm in patients with 


























Average 1.5L consumed per day after 
stroke 
 
Subjects consumed 67% of required 
fluid intake by weight 
 
Mobility issues correlated with poor 
intake (R2=0.064) and elevated BUN/Cr 
ratio (p=0.018) 
NR 2 Adverse events very subjective: 
constipation, urinary tract infection, 
dehydration 
 
Bias – participants were aware of study and 














N NR; NR NR Clinical 
assessment 
 
Urea: creat > 60 
 







SG: urine test 
strips versus 
refractometer 
Nursing assessment: 11/20 (55%) of 
subjects were dehydrated compared with 
45% by urine SG 
 
70/174 urine samples (40%) agreement 
strips with refractometer 
NR 3 The only study to include clinical 
assessment of any kind 
 
Pilot study results do not support use of 
urine test strips to detect dehydration 













ratio > 80 
927 
(36%) 
Mortality 687/1580 (43%) dehydrated patients 
died in hospital v. 177/969 (18%) 
without dehydration (p< 0.0001) 
 
Odds of good outcome if dehydrated 
0.17, 95% CI 0.13, 0.23) 
NR 3 Outcome measure not well defined 
 
Major limitation is lack of a gold standard 

















Death or nursing 
home 
2.2 increased odds worse 30 day 
outcome if dehydrated  despite more 
being treated with tPA (22 v 11%, 
p=0.04) 
30d 3 ONLY STUDY REPORTING RACE: 31% 
African American, 6% Hispanic 
 
Less than 20% of African Americans were 













< 3 days Whole blood 
viscosity 
NR Stroke type v 
viscosity 
DBV  274.7 small artery stroke v 215 
large artery stroke (o 0.003) 
NR 3 No comparison to non-stroke; no functional 
outcomes; 16 stroke mimics  
Table1 Legend: NR= not reported; Dehyd = dehydrated; Stroke type: I=ischemic; H= hemorrhagic; 3=both; BUN/Cr = blood urea nitrogen to creatinine ratio; Urine SG = specific gravity; s osm = serum osmolarity; SIE = stroke in 





























































































































































































































































ROC analysis: 1654 mL 
predicted malignant brain 
edema with 84% 
sensitivity and 68% 
specificity 
 
 43% died in 12 month 
follow-up period 
3 Retrospective design; Inclusion 
criteria for large ischemic stroke; tPA 
to 24%; Decompressive surgery 18% 
 
Fluid type not specified (isotonic, 














6 v 6 






NIHSS > 4 
points) 
Less experienced SIE in 
rehydration group (9 v 21; 
p=0.026) 
2 Change in definition of SIE from 
prior studies 
























mRS < 2 at 
3 months 
Hydration group with 
better 3 mo outcome 
65/134  (p=0.016); 
lacunar group better with 
hydration 
2 tPA patients excluded 
 
mean volume IVF infused 3.9L v 






















Intervention group: 4.2L 
and control 2.4 L 





















Infection lower in 
rehydration group (7.5% v 
17.5% (p=0.018) 
 
LOS shorter in 
rehydration group (10 v 
16 days P = 0.001)  
Intervention: (fluid bolus plus 40-80 
mL/hour IVF x 3d) 
Control: (IVF 40-60 mL/hr x 24 h) 
 
Selection bias – controls prior to 
intervention group 
 
Infection defined as the need for 
antibiotics 
 
Adverse events cerebral edema equal 












24h 24mo Serum osmolarity Not specified Stroke 
recurrence 
Recurrent stroke event: 
16.8% low fluid intake v 
12.3% high fluid intake 
(p=0.013) 
 
3 Controls drank < 2L/day compared to 
intervention > 2L intake per day 
 
Add on to a drug RCT – did not 
report baseline stroke severity 
Table 2 legend: NIHSS = NIH stroke scale score; tPA = tissue plasminogen activator; BUN/Cr = blood urea nitrogen to creatinine ration; IVF = intravenous fluid; L=liters; Q= Quasi-experimental design; 













Chapter 3. Association between volume contracted state and outcome in acute 
ischemic stroke patients who present to hospital within 4.5 hours from symptom onset 
 
Abstract: Elevated BUN/creatinine ratio suggestive of a volume contracted state (VCS) is 
common after acute ischemic stroke and associated with early neurological worsening and worse 
clinical outcome. Whether VCS influences the effect of medical reperfusion treatment is unknown. 
We assessed whether increased BUN/creatinine ratio influences the administration of tissue 
plasminogen activator (tPA) or modifies the effect of tPA benefit in patients with acute ischemic 
stroke. 
 
Methods: We collected data for all patients admitted to the Johns Hopkins Comprehensive Stroke 
center within 4.5 hours of symptom onset for acute ischemic stroke. VCS was defined as 
BUN/creatinine ratio > 15. The primary outcome measures, in separate logistic regression 
models, were administration of tPA and the adjusted odds ratio for good functional outcome 
defined as the achievement of modified Rankin score 0-2, at 90 days post-stroke. Secondary 
outcome variables included early neurological worsening and the development of intracranial 
hemorrhage after tPA.  
 
Results: Of the 382 patients identified, 326 were eligible for inclusion. Patients in a VCS 
demonstrated reduced odds of achieving a good functional outcome defined as modified Rankin 
score 0-2 (bivariate OR 0.56, 95% CI 0.33, 0.95; p=0.030). Of the total cohort, 181 were treated 
with tPA; there was no difference in tPA administration by hydration status (56% were in a VCS 
and 55% were not) nor was there evidence for effect modification of tPA by hydration status (OR 
0.49 95% CI 0.17, 1.43; p=0.193). We found an important qualitative difference in good 3 month 
outcomes for tPA treated patients who were and who were not in a VCS at the time of 
hospitalization (OR 0.81 CI 0.37, 1.76, p=0.60  versus OR 1.66 0.79, 3.49; p=0.182, respectively. 
There was no relationship to the development of post-tPA intracerebral hemorrhage between VCS 
and non-VCS patients (8% versus 14% respectively, p=0.215). 
 
Conclusions: We found no difference in tPA administration based on baseline BUN/creatinine 
ratio. Benefit from tPA may be reduced in patients who have an elevated BUN/creatinine ratio at 






Background: Tissue plasminogen activator (tPA) is the only FDA approved medical treatment 
for acute ischemic stroke and improves functional outcome in the percentage of patients eligible 
to receive the time sensitive medication.1 Selection of patients appropriate for this treatment is 
made based on multiple factors including presentation to a tPA-capable hospital within 4.5 hours 
from stroke symptom onset.2-3 Despite compelling data emphasizing the positive benefit from tPA, 
many patients do not achieve the expected result, and have significant disability despite having 
received tPA.3 Understanding who is at high risk for bad outcome despite tPA, and whether there 
are modifiable factors impacting this outcome is a critical area for further study. Hydration status 
at the time of tPA administration may be one such variable. 
 
Recent studies have suggested that more than half of acute ischemic stroke patients present to 
the hospital in a dehydrated or volume contracted state (using an indirect lab measurement of 
elevated blood urea nitrogen (BUN) to creatinine ratio) and that these patients have worse 
outcome.4-6  Serum BUN/creatinine is an indirect marker for intravascular volume status, and the 
treatment of elevated BUN/creatinine ratio typically includes the administration of isotonic fluids 
to correct this physiological abnormality. A volume contracted state has been associated with 
more severe hemispatial neglect, more frequent early neurological worsening, and poor 3 month 
functional outcomes.7,8 Possible underlying mechanisms of the association between a VCS and 
poor outcome in stroke patients include hemodynamic changes that decrease cerebral perfusion 
in the setting of disrupted cerebral autoregulation, and increased blood viscosity via alterations in 
coagulation activity.9 More recently, observational studies describe an association between 
dehydration and poor outcome in tPA treated patients,10,11 but these studies do not include a 
comparison group of non-tPA treated patients in a similar time window, so it is unknown if 
dehydration status modifies the expected good outcome resulting from tPA administration. To our 
knowledge, no animal models nor human clinical trials have reported whether VCS alters the 
treatment effect of tPA on functional outcome. 
 
We hypothesize that patients in VCS may also have a unique panel of comorbid conditions 
influencing the likelihood of receiving tPA (both due to physician decision and due to 
contraindication due to comorbidity) and, given the above described mechanisms for an effect of 
VCS on poor outcome, hypothesized that a VCS might reduce efficacy of tPA effect. In this single-
center study, we tested the relationship between VCS and tPA administration, and whether VCS 




Methods: This is a retrospective observational study of acute ischemic stroke patients admitted 
to an urban, comprehensive stroke center between 2011 and 2016. The study site is a 
comprehensive stroke center certified by the Joint Commission.  tPA is administered by stroke 
specialists according to American Heart Association guidelines.12 Patients were included if they 
were diagnosed with ischemic stroke within 4.5 hours from symptom onset. Patients were 
excluded if they had history of kidney disease, baseline serum creatinine > 2 or underwent 
mechanical thrombectomy. Clinicians making decisions at the time of tPA administration were 
blinded to the hypothesis of this study. This study was approved by the institutional review board 
of the Johns Hopkins University School of Medicine. 
 
Measures: Baseline demographic, relevant comorbid conditions and home medication use, 
hemodynamic measurements, and stroke severity indicators were compared between the group 
of patients receiving tPA. The assessed clinical parameters were from the medical record and 
included age, gender, common vascular risk factors such as hypertension, atrial fibrillation, and 
diabetes, baseline mean arterial pressure, markers of stroke severity, and serum markers relevant 
to hydration status including serum sodium and glucose.13 Labs are measured upon arrival for 
evaluation of acute stroke in anticipation of potential tPA administration. 
 
Exposure: Bloodwork to measure BUN/creatinine ratio is collected as routine standard of care at 
the time of acute stroke evaluation. Volume contracted state defined as BUN/creatinine ratio >15 
during emergency evaluation was the independent variable when investigating whether tPA 
administration was modified by hydration status.  
 
Outcomes: Primary outcomes were 1) administration of tPA and 2) achievement of good 
functional outcome defined as a 3-month modified Rankin score 0-2 measured by the stroke 
center nursing staff who were blinded to the hypotheses of this study, as a part of routine stroke 
care.  Secondary outcomes included evidence of 1) early neurological worsening defined as 
increase in NIHSS >3 points or death, 2) development of intracerebral hemorrhage defined as 
any symptomatic or asymptomatic hemorrhage after tPA as documented by the stroke 
neurologists caring for the patient at the time of stroke admission.  
Statistical analysis: Characteristics were compared between the group who received tPA and 
those who did not using t-tests (continuous variables) and chi-squared tests (categorical 




Adjustments were made for known covariates that influence functional outcome after stroke 
including age, initial NIHSS score, initial mean arterial pressure, and history of atrial fibrillation.14 
VCS was the moderator variable of interest when investigating the relationship between tPA and 
functional outcome.  
TPA treatment effect modification by admission BUN/creatinine ratio or VCS was assessed by 
including interaction of these variables after binarizing tPA treated patients with good functional 
outcome (mRS 0-2) and poor outcome (mRS >2). We additionally performed a subgroup analysis 
of functional outcome defined as modified Rankin score 0-2 after excluding patients with mild 
stroke defined as NIHSS 1 or who were rapidly improving as the reason for tPA exclusion since 
these patients would likely have a good outcome despite the intervention. Finally, we explored 
functional outcome under the assumption that all missing modified Rankin scores were in the 
worst possible outcome category (mRS >2). Significance was considered p< 0.05. Statistical 
analysis was performed using Stata version 15 (Stata Statistical Software: Release 15, College 
Station, Texas). 
 
Results: Admission BUN/creatinine ratios were available for all 382 patients who presented with 
ischemic stroke within 4.5 hours. Of those, 56 were excluded for the following reasons: additional 
treatment with mechanical thrombectomy (12), history of kidney disease (23), serum creatinine 
>2 (21) leaving 326 subjects available for analysis. Forty seven percent (154 of 326) of the sample 
were in a volume contracted state at the time of admission. Average BUN/creatinine ratio was 16. 
In 240/326 subjects with 3 month modified Rankin scores available, odds of achieving a good 
functional outcome defined as modified Rankin score 0-2 differed for those who were in a VCS 
(bivariate OR 0.56, 95% CI 0.33, 0.95; p=0.030). 
 
Thrombolysis (TPA): Intravenous thrombolysis was administered to 181/326 (56%) of patients 
admitted within 4.5 hours from stroke symptom onset. tPA-treated patients were younger, had 
higher average NIHSS scores, had elevated mean arterial pressures, higher heart rates, and 
higher serum hemoglobin/hematocrits. See Table 1. The reasons that tPA was not administered 
to the 145/326 (44%) were documented for 121 (83%) patients. Most common reasons that tPA 
was not administered to this group included: symptoms too mild or rapidly improving (48%); taking 
anticoagulation or elevated INR (12%); bleeding risks (12%); or changes on CT scan (12%). Other 
exclusions like recent stroke, blood pressure issues, or patient refusal were less frequent. There 




94/181 (55%) who were not in a VCS (p=0.738). Time from symptom onset to tPA administration 
did not differ between groups in a VCS and those who were not (157 versus 154 minutes; 
p=0.784).  
 
Functional outcome: Three-month modified Rankin scores were available for 240/326 (74%) 
patients. In the entire cohort, 150/240 (63%) achieved a good outcome predefined as mRS 0-2. 
In the total cohort, tPA use was not associated with good outcome, but when removed mild stroke 
from non-tPA group 1.65 increased odds of good outcome (95% CI 0.91, 3.01; p=0.101). In the 
entire cohort, there was a significantly reduced odds of good outcome for every unit increase in 
BUN/creatinine ratio (OR 0.94, 95% CI 0.90, 0.99; p=0.012) compared to those who were not in 
a VCS. This relationship persisted in multivariable analysis adjusted for age, initial NIHSS, tPA 
administration, initial mean arterial pressure, and history of atrial fibrillation (OR 0.95; CI 0.91, 
0.99; p=0.046). See table 2.  
 
Tissue Plasminogen Activator group: In the tPA treated group, 88/138 (64%) achieved a good 
outcome. There is no evidence for moderation of tPA benefit by VCS (p=0.193). While not 
statistically significant, we see an important qualitative difference in good 3 month outcomes 
associated with tPA use in patients who were and who were not in a VCS at the time of 
hospitalization (OR 0.81 CI 0.37, 1.76, p=0.60  versus OR 1.66 0.79, 3.49; p=0.182, respectively). 
If analyzed with missing mRS scored as the worst possible outcome, we see a narrowing in this 
difference (VCS OR 0.88 (95% CI 0.46, 1.70; p=0.713) versus no-VCS 0.70 (95% CI 0.39, 1.28; 
p=0.243). 
 
Sensitivity analysis: In order to compare functional outcomes of those who had not received tPA 
because of mild symptoms, we performed a sensitivity analysis by removing the group of patients 
who were rapidly improving or had a mild stroke. In this subgroup of 106 patients, the odds of 
achieving a good outcome associated with tPA was 2.48 (95% CI 1.06, 5.82, p=0.037) in patients 
who were euvolemic compared with a 1.13 increased odds of good outcome in the group who 
were in a VCS at the time of presentation (CI 0.48, 2.68, p=0.783) (p interaction =0.204).  
 
Early Complications: Among tPA treated patients, 8/9 (89%) of people who demonstrated early 
worsening or death were in a VCS compared with 77/170 (45%) who did not worsen. Odds of 
early neurological worsening was increased in tPA treated patients who were in a VCS compared 




(3.3%) and 20 (11%) total ICH (symptomatic and asymptomatic ICH combined). We did not 
observe a difference in post-tPA hemorrhage based on BUN/creatinine ratio at the time of tPA 
treatment adjusted OR 0.61 (95% CI 0.21, 1.76; p=0.361). See Table 3.   
  
Discussion: In this single-center study, we found that patients presenting within 4.5 hours after 
stroke who were dehydrated were not differentially treated with regards to tPA administration, but 
we found some evidence that 3-month benefit from tPA was reduced in individuals with a volume 
contracted state. This relationship was particularly clear when we excluded those individuals who 
did not receive tPA because of rapidly resolving or mild strokes (and thus their inclusion might 
dilute the benefit from tPA.  
 
To our knowledge, no other studies have investigated possibility of modification of tPA effect by 
VCS. Other studies reported an association between dehydration and poor functional outcome 
after tPA, but did not consider individuals who did not receive tPA.10,11 This study demonstrates 
similar rates of VCS as cited in prior studies.15-18 While there was no statistically significant tPA 
effect modification on functional outcome by VCS in the overall sample, qualitative comparison 
suggests that odds of achieving a good functional outcome are notably different between groups 
who were and were not in a VCS at the time of tPA. This is an important clinical finding, especially 
in the context of recent studies of intravenous fluid after ischemic stroke.19,20 Furthermore, we find 
stronger evidence of differences between these groups when we eliminate individuals who would 
not be considered eligible for tPA even within this time window (the rapidly resolving, or minor 
stroke group), allowing us to consider tPA’s benefit more fairly. The fact that the overall benefit of 
tPA, regardless of hydration status, is not seen until we conducted this sensitivity analysis, is 
evidence of the importance of considering VCS as we consider the potential to improve outcomes 
for stroke patients. 
 
The potential to modify the association between VCS and outcome hasn’t been studied for stroke 
patients receiving tPA, but has been studied more broadly. In a recently completed randomized 
trial, Suwanwela and colleagues demonstrated that administration of normal saline at 100mL/hour 
for 72 hours after arrival to the hospital with ischemic stroke was safe and associated with 
decreased early neurological worsening.19 This was consistent with a prior, unblinded, Phase II 
single site study of saline bolus followed by 40-80mL/hour of saline administered for 72 hours.20 
These studies excluded patients who received thrombolytic therapy and enrolled patients up to 




of patients who are within 4.5 hours from stroke symptoms onset. Specifically, disrupted cerebral 
autoregulation makes the patient more vulnerable to changes in intravascular volume and thus 
cerebral perfusion. A VCS may contribute to the distribution of tPA and medication 
pharmacokinetics as seen in other studies of medications in animal models.21 
 
In addition to the retrospective study design, this study has several limitations to consider. First, 
BUN/creatinine ratio is an indirect marker of VCS and can be affected by other conditions.22-26 
While we attempted to reduce the risk of these events with our exclusion criteria and analysis of 
relevant co-variates, elevated BUN/creatinine ratio may simply reflect a yet unmeasurable “sicker” 
population of stroke patients.27 Second, low initial NIHSS in the non-treated group created a floor 
effect impacting secondary analysis looking for change in NIHSS. Next, we do not have 
information about amount of intravenous fluid administered to this population in order to measure 
treatment differences and how these might impact outcome. Future prospective studies will 
include this important variable. There are likely additional unmeasured confounders contributing 
to the outcomes that aren’t well captured and wouldn’t be adjustable but might relate to VCS and 
thus lead to differences that we can’t account for.28 Early neurological worsening was notable 
more often in patients in a VCS however the low number of patients who worsened make this 
difficult to interpret and will need to be explored in future studies. Finally, missingness of the 3 
month modified Rankin score must be considered. It is possible that those patients with missing 
mRS may reflect patients with the worse functional outcomes. Thus we undertook an analysis 
that scored any missing mRS as the worse outcome which showed a narrowing in that difference. 
Considering these results together, it is likely that the truth lies somewhere between these two 
extremes and will need consideration in future prospective trials. Strengths of our study are that 
this is a cohort of all ischemic stroke patients who present with stroke symptoms within 4.5 hours 
from symptom onset. It is a real-world data sample managed by a consistent team of vascular 
neurologists who administer tPA based on American Heart Association guidelines.12  
 
Conclusion: We demonstrated that VCS was not associated with a difference in tPA 
administration rates but may decrease the odds of achieving a good 3 month functional outcome. 
Future studies are needed to explore this relationship and consider whether early correction of a 
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Table 1. Demographics for TPA versus non-TPA treated patients presenting to Johns Hopkins 























































Initial NIHSS score 6.9 (6.3) 7.9 (5.9) 5.6 (6.5) 0.001 
Ejection fraction 








BUN/creatinine ratio  
 
16 (6) 15 (5) 16 (8) 0.241 
Initial Mean Arterial 
Pressure (mmHg) 
112 (20) 114 (20) 109 (20) 0.031 
Systolic blood 
pressure (mmHg) 
160 (32) 162 (33) 157 (30) 0.164 
Diastolic blood 
pressure (mmHg) 
88 (17) 90 (16) 85 (18) 0.012 
Heart rate (bpm) 85 (20) 87 (23) 82 (17) 0.035 
Serum Sodium 
mEq/L 
140 (4) 140 (3) 140 (4) 0.475 
Serum glucose 
(mg/dL) 
133 (66) 133 (69) 133 (62) 0.997 
Serum Hemoglobin 
(mg/dL) 
13 (2) 14 (2) 13(2) 0.005 
Serum Hematocrit 
(%) 
40 (5) 40 (5) 39 (6) 0.012 





1.017 (0.010) 1.018 (0.011) 0.592 
Length of stay 
(days) 
5.8 (7.4) 6 (9) 5 (5) 0.127 
*Mean (SD) unless otherwise specified; Chi-square for dichotomous variables N(%); t-test for continuous variables displayed as 
mean (SD); BUN=blood urea nitrogen (BUN/creatinine ratio is the indirect marker for volume contracted state); NIHSS = 






Table 2. Logistic regression prediction of good 3 month functional outcome defined as modified 
Rankin score of 0-2 (N=234) 
 









Initial NIHSS score 0.90 
(0.86, 0.95) 
<0.001 















Table 3. Odds of hemorrhagic complication after tPA administration for ischemic stroke 
(N=179) 









Initial NIHSS  1.04 
(0.96, 1.13) 
0.315 
Initial Mean arterial pressure 1.02 
(0.99, 1.04) 
0.142 
Baseline Hemoglobin 1.14 
(0.85, 1.54) 
0.382 
Atrial fibrillation 2.20 
(0.64, 7.53) 
0.211 





Chapter 4: Volume contracted state and outcomes in patients with acute 
ischemic stroke patients undergoing mechanical thrombectomy 
 
Abstract: Impaired hydration measured by elevated blood urea nitrogen (BUN) to creatinine ratio 
has been associated with worsened outcome after acute ischemic stroke. Whether hydration 
status is relevant for patients with acute ischemic stroke treated with mechanical thrombectomy 
remains unknown.  
 
Materials and Methods: We conducted a retrospective review of consecutive acute ischemic 
stroke patients who underwent endovascular procedures for anterior circulation large artery 
occlusion at Johns Hopkins Comprehensive Stroke Centers between 2012 and 2017. A volume 
contracted state (VCS), was determined based on surrogate lab markers and defined as blood 
urea nitrogen (BUN) to creatinine ratio greater than 15. Endpoints were achievement of successful 
revascularization (TICI 2b or 3), early re-occlusion, and short term clinical outcomes including 
development of early neurological worsening and functional outcome at 3 months.  
 
Results: Of the 158 patients who underwent an endovascular procedure, 102 patients had a final 
diagnosis of anterior circulation large vessel occlusion and met the inclusion criteria for analysis. 
Volume contracted state was present in 62/102 (61%) of patients. Successful revascularization 
was achieved in 75/102 (74%) of the cohort. There was no relationship between VCS and 
successful revascularization, but there was a 1.13 increased adjusted odds (95% CI 1.01, 1.27) 
of re-occlusion within 24 hours for every point higher BUN/creatinine ratio in the subset of patients 
who underwent radiological testing for pre-procedure planning (n=57). There was no relationship 
between VCS and clinical outcomes including early neurological worsening and 3 month outcome.  
 
Conclusions: Patients with VCS and large vessel anterior circulation stroke may have a higher 
odds of early re-occlusion after mechanical thrombectomy than their non-VCS counterparts, but 
no differences in successful revascularization nor clinical outcomes were present in this cohort. 






Background: Ischemic stroke is a common and disabling condition.1 Patients presenting with 
stroke and a volume contracted state (measured through elevated blood urea nitrogen (BUN) to 
creatinine ratio) may have poor clinical outcomes compared to patients who are not in a volume 
contracted state regardless of age or relevant comorbid conditions.2-5  No direct mechanism yet 
explains this relationship but may include alteration in blood viscosity and alteration of cerebral 
perfusion. Acute stroke guidelines recommend that intravenous fluids be administered for those 
in a volume contracted state, but diagnosis of a VCS is subjective and therefore implementation 
of these recommendations, especially during time sensitive stroke treatments is variable.6 Very 
few therapies to reverse the consequences of ischemic stroke are available.  
 
Mechanical thrombectomy is one such procedure and clinical success for this procedure is 
determined based on successful revascularization, avoidance of large artery re-occlusion, 
avoidance of early neurological deterioration, and achievement of good functional outcome often 
defined as modified Rankin scale score between 0-2.7 Selection of patients who may benefit the 
most from this procedure is made based on characteristics including age, stroke severity, and 
presence of collateral circulation.8 The aim of this paper was to evaluate the association between 
admission VCS status and clinical outcomes in patients with acute, large artery ischemic stroke 
who were eligible for mechanical thrombectomy. We hypothesized that, among individuals 
undergoing mechanical thrombectomy for acute ischemic stroke, hydration status at the time of 
stroke may relate to the success of revascularization procedure and early clinical outcomes 
defined as change in neurological status or development of post-procedure hemorrhage. We 
additionally suspected that a VCS at the time of acute stroke would associate with poor functional 
outcomes defined by 3 month modified Rankin scale score. 
 
Methods: This is a retrospective observational study of patients with acute ischemic stroke who 
were admitted to the Johns Hopkins Comprehensive Stroke center with angiogram-confirmed 
large artery stroke in the anterior circulation between 2012 and 2017.  Data were included if the 
patient was suspected to have large artery, acute ischemic stroke eligible for mechanical 
thrombectomy, within 6 hours from stroke onset which was customary for treatment during this 
time.9 Patients were further excluded from this study if they had kidney disease reported in the 
medical history or if serum creatinine was > 2 on arrival, had evidence of active GI bleeding that 
could have elevated BUN, or if stroke was due to occlusion in the posterior circulation. 




excluded. This study was approved by the Johns Hopkins Medical Institutions IRB and this report 
is generated using STROBE guidelines.10 
 
Definitions:  
Setting and Measures: Patients are evaluated for eligibility for mechanical thrombectomy by a 
single stroke team at the Johns Hopkins Comprehensive Stroke center.7  Cerebral angiograms 
and mechanical thrombectomy were and are performed by a single stroke team that serves two 
campuses separated by less than 10 miles in distance; therefore, no technical differences existed 
between the two groups. Medical histories included report of hypertension, heart failure, atrial 
fibrillation, and any cancer. Kidney disease was defined as patient reported chronic kidney 
disease or serum creatinine > 2. Physiological variables collected were mean arterial pressure 
measured upon arrival to the emergency department. Intravascular volume status was measured 
indirectly using the surrogate marker of elevated blood urea nitrogen to creatinine ration 
(BUN/creatinine ratio). Stroke severity was measured using NIH stroke scale score by the treating 
team at baseline and 24 hours after the procedure. Alberta Stroke Program Early CT scores 
(ASPECTS) were calculated using standard approaches by a stroke neurologist blinded to the 
hydration status of the patient.11 
  
Angiographic procedure and grading of collateral circulation:  
Baseline leptomeningeal collaterals were assessed on CT angiograms that were obtained during 
standard of care operations. Two independent, blinded experienced readers (vascular neurology; 
vascular neuroradiology) scored collateral patterns as favorable or unfavorable using the Metiff 
scoring system commonly used in stroke populations.12,13 A third rater adjudicated discrepancies. 
Contrast filling greater or equal to 50% on the side of infarct was considered good collateral flow, 
and contrast filling less than 50% was considered as poor collateral flow. The primary collateral 
scale was then binarized as favorable or unfavorable collateral patterns using predefined 
definitions.13 Successful revascularization was assessed using the thrombolysis in ischemic 
cerebral infarction (TICI) scale and measured immediately after the completion of each attempted 
intervention by specialists who were blinded to the hypothesis of this study.8 Post procedure TICI 
scores of 2b or 3 were considered a good revascularization outcome.8,14 Re-occlusion after 24 
hours was assessed for any patient who required repeat vascular imaging (CT or MR) as a part 





Clinical outcomes: The NIHSS was measured and recorded by the primary clinical team, as per 
standard practice, at baseline and at 24 hours post-procedure. Early neurological worsening was 
defined as an increase in NIHSS > 3 points in the first 24 hours after attempted mechanical 
thrombectomy.17 Functional outcomes were measured by stroke center nurses per clinical routine 
3 month months after stroke using the modified Rankin score. Poor outcome was predefined as 
modified Rankin score >2. Symptomatic and asymptomatic intracerebral hemorrhage were 
analyzed as per standard acute stroke treatment definitions. All clinical scores were generated by 
stroke team providers who were blinded to the hypotheses of this study. 
 
Statistical plan: The primary outcome of interest was successful revascularization. Independent 
variable was volume contracted state both as a continuous variable (BUN/creatinine ratio) and 
dichotomous value (VCS yes or no). Secondary outcomes included large vessel reocclusion after 
24 hours, early neurological worsening defined as increase in NIHSS score > 3 points in the first 
24 hours, and odds of poor functional outcome defined as mRS 0-2 after 3 months.16-18 
 
Bivariate comparisons of relevant medical and hemodynamic factors between the groups of 
patients in VCS and non-VCS states were made using independent t-tests or chi-squared tests 
of association. In multivariable analyses, potential confounding variables were identified by 
physiological plausibility and included in the models.18 Statistical analysis was completed using 
Stata/IC 15.0. 
 
Power analysis: Prior data indicate that approximately 50% of the cohort would be in a volume 
contracted state and that 60% of the group would achieve the primary endpoint of good 
revascularization.18-23 Therefore we anticipated needing 94 total cases (47 in each hydration 
group) to test our hypothesis with power 0.8. Statistical significance for all analyses was evaluated 
at p< 0.05.  
 
Results: Of the 158 patients eligible for participation, 56 were excluded for the following reasons: 
history of renal failure (16), creatinine >2 (18), posterior circulation occlusion (14), cervical 
common carotid artery occlusion without intracranial lesion (8). The average age was 65 years; 
32% of patients were African American, 58% white. Strokes were moderately large (with average 
initial NIHSS was 15 (+7)), and more than half (62/102, or 61%) were categorized in a VCS.  
Although by definition all patients underwent mechanical thrombectomy, in 53/102 (53%) this was 




angiogram with unfavorable collateral pattern observed in 16 (27%). There was no difference in 
unfavorable collateral pattern for patients in a VCS and those who were not (p=0.11). Subjects in 
a VCS were older (p=0.001) and more often had history of hypertension (p=0.01). See Table 1 
for additional detail. 
 
Successful revascularization: Of the 102 subjects, 75 (74%) achieved successful 
revascularization defined as TICI 2b/3.  Current smoking was the only characteristic associated 
with reduced chance for successful revascularization (adjusted OR 0.30; 95% CI 0.09, 0.96). See 
Table 2. Patients in a volume contracted state had similar odds of good revascularization with 
mechanical thrombectomy as did those with euvolemia; unadjusted OR 1.01 (95% CI; 0.95; 1.08; 
p=0.78). There was no significant relationship between VCS and achievement of successful 
revascularization (unadjusted OR 1.01; 95% CI 0.94, 1.08; p=0.86). 
 
Large vessel re-occlusion at 24 hours: There were 67 patients with repeat CT or MRI scan and 
sufficient radiographic data to evaluate the development of re-occlusion within 24 hours after 
mechanical thrombectomy. Of those, 14/67 (21%) demonstrated re-occlusion. There was an 
increased odds of re-occlusion for every point increase in BUN/creatinine ratio and this 
association persisted after adjusting for age, history of hypertension, current smoking, serum 
glucose, and administration of thrombolytic medication (OR 1.13; 95% CI 1.01, 1.27). See Table 
3. 
 
Clinical outcomes: In this cohort, 19/102 (19%) patients demonstrated early neurological 
worsening by pre-specified NIHSS score criteria. For every 1 point increase in BUN/creatinine 
ratio there was 1.04-times increased odds of early neurological worsening (95% CI 1.00, 1.15; 
p=0.05) but this relationship did not persist in multivariable regression analysis (p=0.22). There 
was no relationship between VCS and 3 month modified Rankin score (p=0.98). Age and 
unfavorable collateral circulations were strong predictors of early neurological worsening in the 
subset of 57 patients with baseline vessel imaging prior to mechanical thrombectomy.  See Table 
5. There was no relationship between VCS and hemorrhagic transformation in the 16 patients 







This retrospective observational study assessed the association between VCS, as measured by 
an indirect blood marker, and relevant procedural and clinical outcomes of attempted mechanical 
thrombectomy. In this cohort, there is no relationship between VCS and procedural or clinical 
outcomes in a group of patients with acute ischemic stroke who were eligible for mechanical 
thrombectomy. We found that smoking was strongly associated with reduced likelihood of 
successful revascularization. This differs from studies of the effect of thrombolysis in patients who 
smoke where the “smokers paradox” of good outcome after thrombolysis after MI and stroke has 
been reported.24 It additionally differs from the observational cohort reported where report of 
smoking was reported to be associated with higher rates of arterial recanalization in smokers 
versus nonsmokers (86% versus 79%; p= 0.048). There may be pathophysiological rationale for 
this association in that smoking may lead to greater thrombus burden and/or accelerated 
atherosclerosis raising the complexity of the access to the thrombus via angiographic 
techniques.24-26 
 
We also observed an association between VCS and vessel re-occlusion within 24 hours of 
thrombectomy even after adjustment for clinically relevant factors. Increased odds of vessel re-
occlusion within 24 hours after thrombectomy in patients with VCS is a significant and clinically 
meaningful association that deserves further exploration.27 This finding follows the physiological 
hypotheses driving this study. In a volume contracted state, patients are suspected to be in a 
relatively hyperviscous/pro-thrombotic state which may accelerate re-occlusion in endothelium 
that was recently disrupted by catheter angiography and device deployment for clot extraction. 
We report this relationship with caution as this may represent bias; this subgroup had a clinical 
change warranting this repeated radiographic assessment via CT or MR in order to demonstrate 
re-occlusion. This relationship will need replication using a single radiographic technique in future 
prospective studies. These results suggest that VCS could be a modifiable factor in the durable 
success of mechanical thrombectomy. 
 
Overall, our rates of VCS remain consistent with prior reports.5, 28-29 Differing from the literature, 
we did not observe a difference in collateral circulation based on hydration status as previously 
reported by Chang and colleagues.30  In their series, elevated BUN/Creatinine ratio was related 
to poor collateral circulation based on magnetic resonance imaging in 87 subjects (p=0.001). The 
differences between our results and those reported by Chang et al could be explained in several 
ways including the differences in the subjects included (tPA patients were excluded in the Chang 




assessment of the relationship between hydration status and collateral circulation in larger cohorts 
would be valuable. 
 
Aside from age, collateral circulation was the only variable strongly associated with clinical 
outcomes in our cohort. Regardless of hydration status, collateral status is again demonstrated 
to be an important determinant of final infarct size. Collateral circulation in the brain generally 
refers to subsidiary vascular networks that provide redundant blood supply to cells and help 
stabilize cerebral blood flow whenever primary channels are impaired. In the event of ischemic 
stroke, collaterals serve to provide a temporary blood supply to hypoperfused tissue at risk of 
infarction. As such, good collateral circulation has been identified as an independent determinant 
of favorable stroke outcome, regardless of treatment. It also has been associated with slower 
infarct growth, lower volume of hypoperfusion, lessened stroke severity, greater penumbra/core 
mismatch (greater penumbra, smaller core), and faster, more effective revascularization results 
after mechanical thrombectomy. Furthermore, one study has found that patients with good to 
intermediate collaterals benefitted the most from mechanical thrombectomy even after the typical 
6-hour therapeutic window, while patients with poor collaterals tended not to benefit at all from 
mechanical thrombectomy more than 5 hours after onset.31 Another study suggested that 
collateral status may be dynamic on a very short time scale, and may change quickly enough in 
response to hemodynamic fluctuations during stroke to not be categorized based on one testing.32 
Contrary to the original assumption that the severity of the baseline perfusion lesion linearly 
predicts infarct growth, rapid changes in collateral circulation may vary considerably and, in fact, 
potentially cause a worsening of infarct growth.33-35 Therefore we considered that it would be 
biologically plausible that VCS would be relevant to the collateral blood supply in patients with 
stroke. Future studies exploring the relationship between hydration status and outcomes after 
mechanical thrombectomy in an extended time window are needed. 
 
Multiple other limitations common to retrospective design and small sample size are notable. 
Though we only included those who presented to the angiogram suite within 6 hours from stroke 
onset, time of vessel revascularization was not typically recorded at our stroke center during this 
study period and therefore this data is unavailable for analysis. We were not able to include the 
total amount of fluid (intravenous and oral) administration after the procedure in our analysis due 
to inconsistent documentation of these volumes. Post procedure fluid intake may be an important 
modifier of outcomes, particularly for individuals in a VCS. Finally, several clinical variables of 




in the regression analysis since inclusion of additional variables would have led to overfitting of 
the logistical regression models given the small sample size, or were not available.  
It is important to note that this series of mechanical thrombectomy patients was collected prior to 
the release of practice guidelines that standardized stroke center approaches to this therapeutic 
intervention.7 Therefore, the criteria used to select patients based on more favorable imaging 
profiles and standardized selection of clot retrieval devices differed from current practices, and 
might underestimate the good outcomes of the group overall. That said, several important 
observations are notable. First, the average age for those in a VCS is significantly higher than 
among individuals undergoing thrombectomy but not in a VCS, supporting prior reports that 
dehydration is more common in older subjects who may lose their thirst drive or who have 
impaired mobility. In this group, subjects with a history of hypertension were more likely to be in 
a VCS than their counterparts without. This might be related to differences in medications, 
specifically use of diuretics for blood pressure control, though data about baseline medications 
were not available for comparison.  
 
Conclusions: In this cohort, there was no relationship between technically successful 
revascularization and baseline hydration status nor statistically meaningful differences in 
collateral circulation patterns by hydration status. The significant association between volume 
contracted state and higher odds of re-occlusion, amongst patients presenting to the hospital in 
a volume contracted state warrants additional study in a larger cohort. Should this relationship 
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Table 1. Patient characteristics by hydration status at admission (BUN/creatinine ratio)* 












65 (17) 60 (17) 68 (16) 0.01 
Sex (Female) 54 (53) 18 (45%) 36 (58%) 0.20 















Atrial fibrillation 36 (35) 14 (35%) 22 (36%) 0.96 
Hypertension 
 
74 (73) 23 (58%) 51 (82%) 0.01 
Diabetes 23 (23) 6 (15%) 17 (27%) 0.14 
Ejection Fraction below 50%^ 23 (24) 12 (32%) 11 (19%) 0.16 
Tissue plasminogen activator 
(tPA) 
53 (52) 20 (50%) 33 (53%) 0.75 
Baseline MAP (mmHg) 
(mean (SD)) 
106 (19) 111 (19) 103 (18) 0.05 
Serum Sodium (mean (SD)) 140 (4) 141 (4) 140 (5) 0.24 
Serum Glucose (mean (SD)) 146 (58) 136 (51) 152 (62) 0.18 
Baseline Hemoglobin (man 
(SD)) 
12 (2) 12 (3) 12 (2) 0.82 
Baseline Hematocrit (mean 
(SD)) 
38 (6) 38 (6) 37 (6) 0.60 
Initial NIHSS 
(mean (SD)) 
15 (7) 16 (7) 15 (6) 0.39 
Initial ASPECTS score (CT) 9 (2) 8.8 (1.3) 8.6 (1.9) 0.51 
Unfavorable collateral 
pattern+ 
16 (27) 3 (14%) 13 (33%) 0.11 
*Results reported as N(%) unless otherwise specified; Chi-square for dichotomous variables N(%); t-test for continuous 
variables displayed as mean (SD);  ^Sample size for patients with available data about ejection fraction is N=96; +Unfavorable 





Table 2: Association of VCS and other clinical variables with achievement of TICI 2b/3 
















































Table 3: Bi- and multivariable logistic regression demonstrating odds of vessel re-occlusion 24 

















































Table 4: Bivariable and multivariable logistical regression to describe: 1) odds of early 




Early Neurological worsening  
(NIHSS) 
Poor 3 month outcome  
(mRS) 






P Odds Ratio 
(CI, 95%) 










































































Chapter 5: Noninvasive monitor to quantify hydration status in ischemic 
stroke patients: a feasibility study 
 
Abstract:  Individuals suffering an acute ischemic stroke are dehydrated, volume contracted or 
both at the time of hospitalization and have worse clinical outcomes. Currently, there is no gold 
standard method for measuring hydration status, except indirect markers of a volume contracted 
state (VCS) including elevated BUN/creatinine ratio, which may supplement a clinical diagnosis. 
Thus a noninvasive and real-time measure of hydration status may have benefit in the early phase 
of acute stroke care. This feasibility study was designed to assess the role of an innovative 
medical technology to measure volume status using non-invasive cardiac output monitoring 
before starting a larger clinical trial. We sought to 1) test the feasibility and acceptability of a non-
invasive cardiac output monitor (NICOM) for the measurement of hydration status in a group of 
hospitalized ischemic stroke patients; 2) compare agreement between commonly used indirect 
lab indicators of VCS (BUN/creatinine ratio) and device-measured VCS (NICOM); and 3) explore 
level of agreement between laboratory and device measures of VCS in common co-morbid 
conditions such as diabetes and heart failure. 
 
Methods: Thirty patients hospitalized with acute ischemic stroke were enrolled into this 
prospective observational feasibility study. Hemodynamic parameters were assessed via NICOM. 
Successful acquisition of relevant hemodynamic data was the primary objective of this study. 
Patients with increase in stroke volume index (SVI) of >10% after delivery of “autobolus” (defined 
by passive leg raise) were considered potentially fluid responsive and thus categorized in a VCS. 
Results of blood urea nitrogen (BUN) and creatinine within 8 hours from NICOM measurement 
were collected from the patient’s medical record and categorized as a VCS if BUN/creatinine ratio 
> 15. Cohen’s kappa statistic was used to evaluate level of agreement between these two 
potential markers of hydration status. 
 
Results: In this group of hospitalized stroke patients, 29 out of 30 tolerated use of the NICOM 
well and hemodynamic data was collected in all 30 patients. Data capture took an average of 10 
min and 15 seconds. Agreement between NICOM and BUN/creatinine ratio was 70%; (expected 
agreement 51%; kappa 0.38). Agreement was better in the cohort without history of diabetes 





Conclusions: NICOM is feasible in hospitalized stroke patients and well-tolerated by this group 
of patients with multiple hemodynamic and comorbid conditions. Agreement with commonly used 
lab markers was moderate, with particularly high agreement in non-diabetic patients. Future 
studies will evaluate device reliability based on the relationship with individual characteristics and 
clinical outcomes. The identification of an objective, real-time measure of hydration status would 




Background:  Stroke is a common cause of death and disability and successful treatments such 
as thrombolysis and mechanical thrombectomy underscore the importance of early intervention 
to decrease the burden of disease.1,2 Post-stroke treatment requires diligent clinical management 
to optimize homeostasis and decrease the risk of complications.2  Stroke disrupts cerebral 
autoregulation leaving the brain reliant on blood pressure and intravascular volume to maintain 
adequate cerebral perfusion.3 Because hydration supports intravascular volume, hydration status 
is a key physiological parameter in post-stroke treatment. Without a gold standard to objectively 
assess hydration status, diagnosis is often subjective and targeted rehydration treatment is 
challenging particularly in the context of concern of airway viability and also fluid overload in 
patients with co-existing cardia disease.4-7 One parameter often incorporated into clinician 
assessment of volume status is elevated blood urea nitrogen (BUN) to creatinine ratio. There is 
accumulating evidence that increased BUN/creatinine ratio, for instance at a level >15 is 
associated with worse outcome after acute ischemic stroke.8-10 This laboratory measurement, 
however, is somewhat invasive, requires blood draw, and has a long lag time for results in many 
hospitals, which can be a disincentive to repeat measurements. Therefore, there is a need in the 
early phase of stroke care for a noninvasive and real time monitor of hydration status.  
 
The role of non-invasive cardiac output monitoring  
In many areas of clinical care reliable and valid measures of assessment are sought after, 
particularly those that are non- invasive and minimize risks to the patient.  Bioimpedance and 
bioreactance analysis systems have been widely investigated due to the non-invasive nature of 
the procedure, the low cost and the portability the devices that estimate body composition in a 
variety of clinical conditions such as chronic heart failure.11-13 The non-invasive cardiac output 
monitor (NICOM) (Cheetah Medical Technology) is a hemodynamic monitor that uses 
bioreactance to measure biventricular volume reserve indicating intravascular volume status. This 
device has been tested against invasive hemodynamic measurement devices including 
pulmonary artery catheter and pulse contour cardiac output (PiCCO) catheters in a variety of 
patient populations with varying results.11,14-16 Passive leg raise technique allows for objective 
determination of fluid responsiveness and therefore can be used to guide rehydration therapy in 
real time.  
 
To date, a noninvasive device such as NICOM has not been tested in patients with stroke or other 
neurological injury, but this population represents a vulnerable group in whom validation may be 




comorbid conditions that make lying flat challenging including aspiration risks, increased chance 
of elevated intracranial pressure, and higher frequency of heart failure. Additionally, these patients 
commonly display hemodynamic instability due to dysautonomia from common conditions like 
diabetic autonomic neuropathy. Prior reports have demonstrated variability in other populations 
with dysautonomia. Thus, in this study we undertook a prospective assessment to determine: (1) 
if the application of device was technically feasible; (2) if the passive leg raise maneuver was 
tolerated by patients; (3) if use of the device was minimally burdensome in the context of clinical 
care; and (4) the level of agreement between diagnosis of VCS using NICOM (device) as 
compared with BUN/creatinine ratio (labs) to evaluate the potential future utility of the NICOM 
device in monitoring hydration status in studies of stroke- related outcome 
 
Materials and Methods: 
Subjects: Patients were eligible for this prospective, observational study if admitted to the Johns 
Hopkins Stroke Center with the diagnosis of ischemic stroke between 2017 and 2019, and if they 
had BUN/creatinine ratio measured (as is routine) during hospital stroke evaluation. Patients were 
not enrolled if baseline creatinine was > 2, if they had documented kidney disease history, or if 
there was concurrent gastrointestinal bleeding or infection noted by the clinical team at the time 
of enrollment. Relevant patient characteristics about comorbid conditions and stroke severity, as 
well as these exclusion criteria, were abstracted from the electronic medical record. We were 
specifically interested in conditions that could affect heart rate variability and autonomic function 
including medications, heart failure and diabetes. The study was approved by the Johns Hopkins 
Institutional Review Board. 
 
Noninvasive cardiac output monitor: The noninvasive cardiac output monitor was used by study 
team members who completed standard device training. Technical details of the NICOM have 
been described previously.17 After the consent process and written consent was signed by the 
patient or legal representative, patients were assisted into a semi-recumbent position and four 
dual NICOM sensors were placed on the chest wall then connected to the portable NICOM 
controller. After baseline readings were obtained, patients were transitioned to a flat position with 
legs elevated in order to deliver the estimated 300cc autobolus to the intravascular system 
through passive leg raise. Relevant hemodynamic parameters, including calculated repeat SVI 




change in SVI was >10% then the patient was considered to be potentially volume responsive 
and labeled as being in a volume contracted state. 
 
Lab defined volume contracted state:  The electronic medical record was then abstracted for 
relevant data including lab results collected nearest to the time of the NICOM measurement and 
within 12 hours from the time of NICOM procedure. BUN/creatinine ratio > 15 was considered a 
volume contracted state as used in prior acute stroke studies.18-21 
 
Statistical plan: The primary outcome was feasibility of successful NICOM hydration 
measurement defined as acquisition of sufficient hemodynamic data to measure change in stroke 
volume index. Bivariate comparisons of study variables including relevant medical history and 
characteristics of stroke severity between groups of patients in VCS and euvolemic states were 
made using independent t-tests and chi-squared tests of association.22 Due to the anticipated 
small sample size in this feasibility study, no multivariable analysis was planned due to risks of 
overfitting models. Bivariate odds ratios and 95% confidence intervals were calculated using 
logistic regression to understand the characteristics of the subgroup in whom labs and device did 
not agree. Statistical significance for all analyses was pre-set at p<0.05. Tests of association 
between lab and device measured VCS was conducted using Cohen’s kappa coefficient. 
Definitive criteria for the interpretation of kappa coefficients have been previously proposed.23 
Values between 0.4 and 0.75 represent moderate to good agreement, and values > 0.75 suggest 
excellent agreement. Statistical analysis was completed using Stata/IC 15.0. 
 
Results: 
This cohort was comprised of 30 patients who were an average of 62 (range 30-84) years of age, 
13/30 (43%) of whom were female, and 5/30 (17%) who reported heart failure in their medical 
history. Average initial NIH Stroke scale score was 10 (range 0-28), reflective of moderate size 
strokes in this group. The average BUN/creatinine ratio was 17 (+ 7), and 63% of this group 
reported daily beta blocker use, with approximately 30% taking a diuretic as a standing medication 
at the time of admission. Though not meeting statistical significance, women appeared to be in a 
VCS more often than men according to the NICOM (59% versus 41%, respectively) but not by 
BUN/creatinine ratio (44% versus 56%, respectively). See Table 1 for individual characteristics. 
The average time to complete hemodynamic assessment with passive leg raise was 10 minutes 




was collected in 30/30 patients and 29/30 tolerated without complaints. One patient who arrived 
to the hospital with atrial fibrillation and rapid ventricular rate reported shortness of breath while 
lying flat near the end of the passive leg raise maneuver for autobolus delivery. This resolved with 
return to a semi-recumbent position. The average time between lab collection and NICOM was 4 
hours and 42 minutes. 
 
A volume contracted state was detected by BUN/creatinine ratio (labs) in 17/30 (57%; mean 
BUN/creatinine ratio =21) compared with 18/30 (60%; mean BUN/creatinine ratio= 19) by NICOM 
(device). Overall, we found agreement between labs and NICOM in 21/30 (70%; k=0.38) 
measurements. See Table 2. Patients with history of diabetes had higher odds of disagreement 
between the device and lab tests (OR 5.31; 95% CI 0.96, 29.29; p=0.06) than patients without 
history of diabetes. In a group of patients who were not diabetic, agreement was 81% (k= 0.61). 
In a subgroup of 5/30 patients, we observed an unexpected phenomenon of SVI decrease upon 
delivery of the autobolus with passive leg raise. There was no association of a SVI decrease with 
age or sex. However, there was increased odds of a decrease in SVI with passive leg raise for 
every 10 mg/dL increase in serum glucose (adjusted OR 1.37; 95%CI 0.99, 1.89; p=0.06). 
 
Discussion: 
In this study we found use of NICOM to categorize volume status is feasible and was acceptable 
to patients. We found that hospitalized ischemic stroke patients tolerated the positioning required 
for NICOM measurement of VCS with the exception of 1 patient who experienced transient 
shortness of breath during the passive leg raise maneuver. The device was otherwise easy to use 
and data was analyzable in all cases. The NICOM (device) demonstrated fair agreement with 
BUN/creatinine ratio (by labs), although interestingly, that agreement improved for the subset of 
patients without history of diabetes. 
 
Multiple potential physiological rationale could be considered for this relationship and the stronger 
association between labs and NICOM in non-diabetic patients. First, diabetic patients commonly 
demonstrate cardiovascular autonomic neuropathies.24 These types of dysautonomias can 
impact heart rate variability and could impact stroke volume index since heart rate contributes to 
the measurement of stroke volume index. Additionally, other medications commonly used to 
manage secondary complications of diabetes have heart rate effect and therefore may also 




many medications prescribed to manage comorbid conditions in diabetics are potentially 
dehydrating, or could directly alter the BUN/creatinine ratio, and thus the correlation with NICOM. 
The patients with disagreement between lab and NICOM, measured VCS were notably different 
when considering history of diabetes.  
 
We explored characteristics of the nine subjects where labs and NICOM device disagreed. While 
this group was small, we found a trend toward sex-specific differences in those diagnosed with 
VCS using the NICOM device that were not present by lab definition; women were more often in 
a VCS according to the NICOM device only. See Figure 3. This has not been previously reported 
in prior studies of monitors using bioreactance and raises the possibility either of the need for sex-
specific parameters in the NICOM algorithm, or in sex-specific parameters in lab-based definition 
of VCS.25,26 This would require additional testing in a larger population, but would be important to 
consider before applying the NICOM device to a larger sample, as its utility might differ in distinct 
clinical populations. 
 
Rates of VCS using either the lab or NICOM device definitions are consistent with the previously 
reported literature.10 Early studies of the NICOM demonstrated high sensitivity and specificity 
against a ‘gold standard’ defined as pulmonary artery catheter.27,28 The passive leg raise is a 
procedure to test fluid responsiveness with relatively high sensitivity and specificity, 86 and 79% 
respectively, when tested against central venous pressure in a population of patients with septic 
shock. Meta-analysis of the passive leg raise technique demonstrated sensitivity and specificity 
were previously reported as 89% and 91% respectively.29 Bioreactance measurement of 
hydration status offers another potential method by which fluid responsiveness might be 
measured, but data have been mixed: while our level of agreement is lower than that reported by 
Jones and colleagues who used bioreactance methods to study hemodynamic changes in healthy 
subjects during exercise,16 recent study of 19 subjects found that bioreactance did not agree with 
thermodilution (concordance 54.8%) suggesting that interpopulation characteristics may influence 
accuracy of hemodynamic measures using bioreactance methods.14 Stroke patients have a 
different panel of highly comorbid conditions. Our study further differs from these described 
studies as elevated BUN/creatinine ratio is an indirect measure of potential volume contracted 
state; we thus chose not to consider the laboratory measures as a “gold standard”, at least by 





This lack of a gold standard hydration measure for comparison in addition to small sample size 
are the major limitations of this study. The comparison between surrogate, indirect markers such 
as BUN/creatinine is an important limitation. For acute stroke patients, it is not feasible to use 
invasive monitors such as pulmonary artery catheters of PiCCO devices in order to measure 
stroke volume. Furthermore, our study was not sufficiently powered to investigate clinical 
outcomes based on NICOM-measured VCS, but there is compelling evidence emphasizing the 
importance of studying volume contraction status in understanding factors associated with stroke 
outcome. Future studies will need to be designed to include the common comorbid conditions in 
regression models investigating clinical outcomes by NICOM-measured hydration status. 
 
Stroke patients with a suspected volume contracted state, measured with elevated 
BUN/creatinine at the time of hospital arrival have worse clinical outcomes including increased 
odds of early neurological worsening, the presence of more severe hemispatial neglect, and the 
potential for worsened functional status at 3 months, and future studies will need to consider if 
NICOM-measured volume status similarly related to meaningful outcome measures.8, 32 
Correction of the VCS may be a low cost solution and an objective, real-time monitor that could 
allow for more precise rehydration with isotonic fluid could yield a similar benefits to those reported 
for patients with sepsis.26 
 
Measurement of intravascular volume in a critically ill population remains one of the more 
challenging clinical tasks and work in this area remains underpinned by limited or conflicting data 
and lack of a clinically feasible gold standard.31 In order to deliver goal directed therapies to correct 
VCS and augment cerebral perfusion in a group of stroke patients, one must identify an objective 
marker on which to base the treatment algorithm.33 Until recently this required the insertion of 
devices to measure cardiac output, central venous pressures and stroke volumes which is not 
warranted in stroke patients with mild-moderate level dehydration in most cases. The potential for 
a low cost, goal directed therapy to improve outcomes for stroke patients who are dehydrated 
necessitates the continued pursuit of identifying an objective, non-invasive measurement 
approach such as NICOM.  
 
Conclusions: Hospitalized ischemic stroke patients tolerated the positional changes required to 
measure volume contracted state using the noninvasive cardiac output monitor. Agreement with 
a currently used lab parameter yielded fair agreement, with especially high agreement in non-
diabetic patients. Further investigation of noninvasive monitoring is necessary before widespread 
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62 (15) 65 (14) 58 (16) 0.27 63 (16) 61 (15) 0.77 
Sex (Female) 
N(%) 
13 (43) 8 (44) 5 (42) 0.88 10 (59) 3 (23) 0.05 
Race (Black) 
N(%) 
17 (57) 10 (56) 7 (58) 0.88 9 (53) 8 (62) 0.64 
Smoker* N(%) 19 (63) 13  (72) 6 (50) 0.22 12 (71) 7 (54) 0.35 
Atrial fibrillation 
N(%) 
4 (13) 3 (17) 1 (8) 0.51 3 (18) 1 (8) 0.43 
Hypertension 
N(%) 
26 (87) 16 (89) 10 (83) 0.66 14 (82) 12 (92) 0.43 
Diabetes N(%) 9 (30) 7 (39) 2 (17) 0.19 4 (24) 5 (38) 0.38 
Heart failure N(%) 5 (17) 3 (17) 2 (17) 0.68 3 (18) 2 (15) 0.87 
Ejection Fraction 
below 50% N(%) 




4 (13) 3 (17) 1 (8) 0.51 3 (18) 1 (8) 0.43 
Home diuretic N(%) 10 (33) 7 (39) 3 (25) 0.43 2 (15) 8 (47) 0.07 
Baseline heart rate 77 (18) 79 (22) 74 (10) 0.40 76 (22)  78 (13) 0.84 
Baseline mean arterial 
pressure (mmHg) 
96 (16) 94 (13) 99 (19) 0.37 92 (13) 100 (18) 0.18 
Serum Sodium (dL) 142 (3) 141 (3) 142 (4) 0.64 142 (3) 141 (3) 0.64 
Serum Glucose  125 (38) 134 (41) 118 (41) 0.32 120 (32) 138 (50) 0.24 
Baseline Hemoglobin  13 (2) 13 (2) 14 (1) 0.28 14 (2)  13 (2)  0.27 
Baseline Hematocrit  40 (5) 40 (6) 41 (4) 0.53 42 (5)  39 (5) 0.19 
Mean Initial NIHSS 
 
10 (9) 11 (9) 10 (10) 0.85 9 (9) 12 (9) 0.35 
NICOM= noninvasive cardiac output monitor; Values are mean (SD) unless otherwise described; 
*Smoking=ever (current or past); NIHSS = NIH Stroke Scale Score; Continuous variables with ttest; 






Table 2. Comparing measures of hydration status: VCS by labs compared with noninvasive cardiac 
output monitor 
 Lab-measured Hydration 
 (BUN/creatinine ratio) 
Dehydrated 
 (VCS) 





























































Figure 1: Display from two representative patients without and with evidence of fluid 
responsiveness during fluid challenge testing 
   
 
  
NICOM suggests no evidence of fluid 
responsiveness. If clinician treated 
volume contracted state in this patient 
may be an increased risk for volume 
overload or complications. 
 
NICOM suggests fluid responsiveness 
consistent with volume contracted state. 
If clinician treated volume contracted 
state, may have benefit to correct this 




Chapter 6. Synthesis and Future Directions 
 
Current stroke guidelines remind us that “there are no data to guide volume and duration of 
parenteral fluid delivery” after stroke.1 Observational studies suggest an association between 
dehydration status and worsened functional outcome. The studies herein sought to fill this gap by 
examining the relationship between a volume contracted state and outcomes after ischemic 
stroke. We additionally tested a novel technology to objectively measure volume status since a 
major barrier to understanding this phenomenon and the safety of fluid replacement in a relatively 
frail population with multiple comorbid conditions including heart failure. Specifically, we observed 
the relationship between hydration status and benefit from the two currently available hyperacute 
treatments, intravenous thrombolysis and mechanical thrombectomy. Our findings underscore the 
importance of biological contributions to overall recovery during early stroke treatment. 
Additionally, we took a first step in evaluating the feasibility of a noninvasive monitor that could 
serve as a real time and objective measure of volume status that could guide more precise 
hydration therapies. 
 
Summary of findings 
In these studies, we will explored the relationship between a volume contracted state (VCS) 
defined by indirect surrogate lab markers and outcome after acute stroke treatment with 
intravascular tPA or mechanical thrombectomy. We then conducted a prospective feasibility 
study of objectively measuring hydration status in a non-invasive, and real-time way using a 
noninvasive cardiac output monitor (NICOM) and patient report of thirst. Subjects for all aims of 
this study were recruited from the Johns Hopkins Comprehensive stroke center. Johns Hopkins 




experts who are certified in the acute treatment of these patients. Together, these data provide 
results from “real-world” treatment experiences. 
 
Results for Aims 1 and 2 suggest that a volume contracted state, defined by elevated baseline 
BUN/creatinine ratio at the time of hyperacute revascularization treatments and measured 
indirectly using BUN/creatinine ratio is associated with early neurological worsening. This is 
clinically important as patients with early neurological worsening have demonstrated worse 
functional outcomes and higher rates of death in prior studies.2 This relationship to decreased tPA 
benefit was observed in aim 1. In aim 2 we demonstrated an important association between early 
vessel re-occlusion un dehydrated patients who underwent mechanical thrombectomy as 
compared to those who were not dehydrated. In aim 3, we determined that a noninvasive cardiac 
output monitor is feasible for use in a population of hospitalized stroke patients and that comorbid 
conditions such as diabetes may impact accuracy of this device. Together these findings augment 
the literature and help to advance this area of science toward a system of more precise patient 
management in the area of post-stroke fluid management. 
 
Implications for Nursing 
The primary purpose of nursing research is to provide evidence for patient care practices that 
promote health and quality outcomes for patients. In the early phase of stroke care, it is nursing 
assessment of neurological changes, and rapid response to clinical changes that are essential 
for best patient outcome. Hydration status is one of the body’s basic physiological needs. In the 
case of hydration status, we are limited by lack of a standard and objective measure of hydration 
status and thus research in this area has been relatively sparse.  This research is a foundational 
step in both understanding the importance of the contributions of hydration to outcomes but in the 




status, then the management of a volume contracted state could be standardized and managed 
by the bedside nurse in order to provide more precise an responsive care to the patients. Next 
phases in this research will include evaluation of outcomes based on amount of intravenous fluid 
delivered to further confirm that this is a modifiable determinant of stroke outcome. Perhaps we 
will one day design and test the benefits of a fluid replacement sliding scale for use by the bedside 
nurse. With the right measure, this knowledge could be applied to other patient populations in 
which hydration status may be an important determinant of success. 
 
Implications for Policy Changes 
Over recent years, stroke guidelines have fluctuated in terms of language to guide hydration 
therapy after ischemic stroke in response to increasing observational data without clinical trial to 
guide official recommendations. Without objective measures, however, this condition is difficult to 
identify with consistency and challenging to determine the best timing and duration of treatment. 
Identification of it is difficult to implement treatments with high fidelity. Lacey and colleagues 
underscored the complexity of dehydration assessment without single objective measure in a 
recently published multidisciplinary consensus about terminology in this area. It will be critical that 
we create a precise algorithm that is guided by objective measures for stroke patients and is 
effective and easy to implement. If we can accomplish this, it would be the first acute stroke 
therapy available to patients world-wide. 
 
Recommendations for Future Research 
The primary focus of this dissertation was to understand the relationship between a volume 
contracted state and benefit of acute ischemic stroke therapies. Next phases of study will examine 
the potential for volume contracted state as a modifiable variable in early stroke recovery. We will 




outcomes. While it will be important to use standard functional measures after stroke like the 
modified Rankin scale, we will also expand exploration to include thirst as an important patient 
reported symptom. This may prove to be challenging in a population of patients with known 
cognitive and language disturbances, but will be an important direction of study. 
 
Additionally, we sought to test the feasibility of a novel technology to assist with the diagnosis of 
a volume contracted state that was objective and 
acceptable to the patients. The next phases of this 
research will need to further validate this technology 
and the relationship between hydration status as 
measured by noninvasive cardiac monitor with 
clinical outcome.  
 
In parallel, my research will shift to examining the 
relationship with various dosages of intravenous 
fluids and clinical outcomes. Using comparative 
effectiveness methodologies, we will need to 
determine the potential to modify patient outcomes 
using the best dose and duration of intravenous fluid 
administration. It is only then that we can deliver the most precise patient care to deliver the right 
treatment to the right patient at the right time. 
 
This research focus fits into a larger research agenda that will attempt to identify and modify 
determinants of early stroke recovery, using technology supported interventions that could allow 
for the delivery of more precise and effective care. The overarching goal is to reduce stroke-
Figure. Adaptation of Meleis’ transition theory 




related disabilities on the long term by implementing healing treatments in the early phase of a 
patient’s care. Stroke remains a leading cause of adult disability and there is a sensitive window 
for brain recovery. Assuring that we deliver care that addresses all of the biological and 
environmental determinants of recovery during that time may have the potential to reduce stroke 
related disability. Using our conceptual framework as a guide, a holistic and comprehensive 
approach to early recovery research will uncover treatment approaches that accelerate or detract 
from patient recovery during this critical time. See Figure. Then once treatments are identified, 
we must combine cutting edge technologies to enrich the care process and concepts of 
implementation science to assure that those treatments are delivered with the highest fidelity. 
This foundation of clinical research is critical as we develop evidence and change the paradigm 
of early stroke care to promote successful recovery for stroke patients. 
 
Summary: Stroke providers currently manage dehydration after stroke without adequate 
evidence for best practice. Taken together, this grant will provide direction for the development 
of future studies that will answer the important questions of if, when and how to rehydrate patients 
after stroke in order to improve patient outcome. This proposal is the starting point; it provides 
foundational data that will inform a future multicenter trial of early, efficient rehydration after 
stroke. This intervention is an example of a low cost and globally available stroke therapy with the 
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